

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
27 December 2001 (27.12.2001)

PCT

(10) International Publication Number
WO 01/97850 A2

(51) International Patent Classification⁷: **A61K 45/06**

(21) International Application Number: PCT/EP01/06976

(22) International Filing Date: 20 June 2001 (20.06.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
00250194.8 23 June 2000 (23.06.2000) EP
00250214.4 28 June 2000 (28.06.2000) EP

(71) Applicant: **SCHERING AKTIENGESELLSCHAFT**
[DE/DE]; Müllerstrasse 178, 13353 Berlin (DE).

(71) Applicants and

(72) Inventors: **SIEMEISTER, Gerhard** [DE/DE]; Reimer-
swalder Steig 26, 13503 Berlin (DE). **HABEREY, Mar-
tin** [DE/DE]; Steinstr. 1, 12169 Berlin (DE). **THIER-
AUCH, Karl-Heinz** [DE/DE]; Hochwildpfad 45, 14169
Berlin (DE).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished
upon receipt of that report*

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: COMBINATIONS AND COMPOSITIONS WHICH INTERFERE WITH VEGF/VEGF AND ANGIOPOIETIN/TIE
RECEPTOR FUNCTION AND THEIR USE (II)

(57) Abstract: The present invention describes the combination of substances interfering with the biological activity of Vascular
Endothelial Growth Factor (VEGF)/VEGF receptor systems (compound I) and substances interfering with the biological function of
Angiopoietin/Tie receptor systems (compound II) for inhibition of vascularization and for cancer treatment.



WO 01/97850 A2

**Combinations and compositions which interfere with VEGF/ VEGF and
angiopoietin/ Tie receptor function and their use (II)**

5 The present invention provides the combination of substances interfering with the biological activity of Vascular Endothelial Growth Factor (VEGF)/VEGF receptor systems (compound I) and substances interfering with the biological function of Angiopoietin/Tie receptor systems (compound II) for inhibition of vascularization and for cancer treatment.

10

Protein ligands and receptor tyrosine kinases that specifically regulate endothelial cell function are substantially involved in physiological as well as in disease-related angiogenesis. These ligand/receptor systems include the Vascular Endothelial Growth Factor (VEGF) and the Angiopoietin (Ang) families, and their
15 receptors, the VEGF receptor family and the tyrosine kinase with immunoglobulin-like and epidermal growth factor homology domains (Tie) family. The members of the two families of receptor tyrosine kinases are expressed primarily on endothelial cells. The VEGF receptor family includes Flt1 (VEGF-R1), Flk1/KDR (VEGF-R2), and Flt4 (VEGF-R3). These receptors are recognized by members of
20 the VEGF-related growth factors in that the ligands of Flt1 are VEGF and placenta growth factor (PIGF), whereas Flk1/KDR binds VEGF, VEGF-C and VEGF-D, and the ligands of Flt4 are VEGF-C and VEGF-D (Nicosia, Am. J. Pathol. 153, 11-16, 1998). The second family of endothelial cell specific receptor tyrosine kinases is represented by Tie1 and Tie2 (also known as Tek). Whereas Tie1 remains an
25 orphan receptor, three secreted glycoprotein ligands of Tie2, Ang1, Ang2, and Ang3/Ang4 have been discovered (Davis et al., Cell 87, 1161-1169, 1996; Maisonpierre et al., Science 277, 55-60, 1997; Valenzuela et al., Proc. Natl. Acad. Sci. USA 96, 1904-1909, 1999; patents: US 5,521,073; US 5,650,490; US 5,814,464).

30

The pivotal role of VEGF and of its receptors during vascular development was exemplified in studies on targeted gene inactivation. Even the heterozygous disruption of the VEGF gene resulted in fatal deficiencies in vascularization (Carmeliet et al., Nature 380, 435-439, 1996; Ferrara et al., Nature 380, 439-442,

1996). Mice carrying homozygous disruptions in either *Flt1* or *Flk1/KDR* gene die in mid-gestation of acute vascular defects. However, the phenotypes are distinct in that *Flk1/KDR* knock-out mice lack both endothelial cells and a developing hematopoietic system (Shalaby et al. *Nature* 376, 62-66, 1995), whereas *Flt1* deficient mice have normal hematopoietic progenitors and endothelial cells, which fail to assemble into functional vessels (Fong et al., 376, 66-70, 1995). Disruption of the *Flt4* gene, whose extensive embryonic expression becomes restricted to lymphatic vessels in adults, revealed an essential role of *Flt4* for the remodeling and maturation of the primary vascular networks into larger blood vessels during early development of the cardiovascular system (Dumont et al., *Science* 282, 946-949, 1998). Consistent with the lymphatic expression of *Flt4* in adults overexpression of VEGF-C in the skin of transgenic mice resulted in lymphatic, but not vascular, endothelial proliferation and vessel enlargement (Jeltsch et al., *Science* 276, 1423-1425, 1997). Moreover, VEGF-C was reported to induce neovascularization in mouse cornea and chicken embryo chorioallantoic membrane models of angiogenesis (Cao et al., *Proc. Natl. Acad. Sci. USA* 95, 14389-14394, 1998).

The second class of endothelial cell specific receptor tyrosine kinases has also been found to be critically involved in the formation and integrity of vasculature. Mice deficient in *Tie1* die of edema and hemorrhage resulting from poor structural integrity of endothelial cells of the microvasculature (Sato et al., *Nature* 376, 70-74, 1995; Rodewald & Sato, *Oncogene* 12, 397-404, 1996). The *Tie2* knock-out phenotype is characterized by immature vessels lacking branching networks and lacking periendothelial support cells (Sato et al., *Nature* 376, 70-74, 1995; Dumont et al., *Genes Dev.* 8, 1897-1909, 1994). Targeted inactivation of the *Tie2* ligand *Ang1*, as well as overexpression of *Ang2*, an inhibitory ligand, resulted in phenotypes similar to the *Tie2* knock out (Maisonpierre et al., *Science* 277, 55-60, 1997; Suri et al., *cell* 87, 1171-1180). Conversely, increased vascularization was observed upon transgenic overexpression of *Ang1* (Suri et al., *Science* 282, 468-471, 1998; Thurston et al., *Science* 286, 2511-2514, 1999).

The results from angiogenic growth factor expression studies in corpus luteum development (Maisonpierre et al., *Science* 277, 55-60, 1997; Goede et al. *Lab.*

Invest. 78, 1385-1394, 1998), studies on blood vessel maturation in the retina (Alon et al., Nature Med. 1, 1024-1028, 1995; Benjamin et al, Development 125, 1591-1598, 1998), and gene targeting and transgenic experiments on Tie2, Ang1, and Ang2, suggest a fundamental role of the Angiopoietin/Tie receptor system in mediating interactions between endothelial cells and surrounding pericytes or smooth muscle cells. Ang1, which is expressed by the periendothelial cells and seems to be expressed constitutively in the adult, is thought to stabilize existing mature vessels. Ang2, the natural antagonist of Ang1 which is expressed by endothelial cells at sites of vessel sprouting, seems to mediate loosening of endothelial-periendothelial cell contacts to allow vascular remodeling and sprouting in cooperation with angiogenesis initiators such as VEGF, or vessel regression in the absence of VEGF (Hanahan, Science 277, 48-50, 1997).

In pathological settings associated with aberrant neovascularization elevated expression of angiogenic growth factors and of their receptors has been observed. Most solid tumors express high levels of VEGF and the VEGF receptors appear predominantly in endothelial cells of vessels surrounding or penetrating the malignant tissue (Plate et al., Cancer Res. 53, 5822-5827, 1993). Interference with the VEGF/VEGF receptor system by means of VEGF-neutralizing antibodies (Kim et al., Nature 362, 841-844, 1993), retroviral expression of dominant negative VEGF receptor variants (Millauer et al., Nature 367, 576-579, 1994), recombinant VEGF-neutralizing receptor variants (Goldman et al., Proc. Natl. Acad. Sci. USA 95, 8795-8800, 1998), or small molecule inhibitors of VEGF receptor tyrosine kinase (Fong et al., Cancer Res. 59, 99-106, 1999; Wedge et al., Cancer Res. 60, 970-975, 2000; Wood et al. Cancer Res. 60, 2178-2189, 2000), or targeting cytotoxic agents via the VEGF/VEGF receptor system (Arora et al., Cancer Res. 59, 183-188, 1999; EP 0696456A2) resulted in reduced tumor growth and tumor vascularization. However, although many tumors were inhibited by interference with the VEGF/VEGF receptor system, others were unaffected (Millauer et al., Cancer Res. 56, 1615-1620, 1996). Human tumors as well as experimental tumor xenografts contain a large number of immature blood vessels that have not yet recruited periendothelial cells. The fraction of immature vessels is in the range of 40% in slow growing prostate cancer and 90% in fast growing glioblastoma. A selective obliteration of immature tumor vessels was observed upon withdrawal of

VEGF by means of downregulation of VEGF transgene expression in a C6 glioblastoma xenograft model. This result is in accordance with a function of VEGF as endothelial cell survival factor. Similarly, in human prostate cancer shutting off VEGF expression as a consequence of androgen-ablation therapy led to selective apoptotic death of endothelial cells in vessels lacking periendothelial cell coverage. In contrast, the fraction of vessels which resisted VEGF withdrawal showed periendothelial cell coverage (Benjamin et al., J. Clin. Invest. 103, 159-165, 1999).

The observation of elevated expression of Tie receptors in the endothelium of metastatic melanomas (Kaipainen et al., Cancer Res. 54, 6571-6577, 1994), in breast carcinomas (Salvén et al., Br. J. Cancer 74, 69-72, 1996), and in tumor xenografts grown in the presence of dominant-negative VEGF receptors (Millauer et al., Cancer Res. 56, 1615-1620, 1996), as well as elevated expression of Flt4 receptors in the endothelium of lymphatic vessels surrounding lymphomas and breast carcinomas (Jussila et al., Cancer Res. 58, 1599-1604, 1998), and of VEGF-C in various human tumor samples (Salvén et al., Am. J. Pathol. 153, 103-108, 1998), suggested these endothelium-specific growth factors and receptors as candidate alternative pathways driving tumor neovascularization. The high upregulation of Ang2 expression already in early tumors has been interpreted in terms of a host defense mechanism against initial cooption of existing blood vessels by the developing tumor. In the absence of VEGF, the coopted vessels undergo regression leading to necrosis within the center of the tumor. Contrarily, hypoxic upregulation of VEGF expression in cooperation with elevated Ang2 expression rescues and supports tumor vascularization and tumor growth at the tumor margin (Holash et al., Science 284, 1994-1998, 1999; Holash et al., Oncogene 18, 5356-5362, 1999).

Interference with Tie2 receptor function by means of Angiopoietin-neutralizing Tie2 variants consisting of the extracellular ligand-binding domain has been shown to result in inhibition of growth and vascularization of experimental tumors (Lin et al., J. Clin. Invest. 103, 159-165, 1999; Lin et al. Proc. Natl. Acad. Sci. USA 95, 8829-8834, 1998; Siemeister et al., Cancer Res. 59, 3185-3191, 1999). Comparing the effects of interference with the endothelium-specific receptor

tyrosine kinase pathways by means of paracrine expression of the respective extracellular receptor domains on the same cellular background demonstrated inhibition of tumor growth upon blockade of the VEGF receptor system and of the Tie2 receptor system, respectively (Siemeister et al., Cancer Res. 59, 3185-3191, 1999).

It is known that the inhibition of the VEGF/VEGR receptor system by various methods resulted only in slowing down growth of most experimental tumors (Millauer et al., Nature 367, 576-579, 1994; Kim et al., Nature 362, 841-844, 1993; Millauer et al., Cancer Res. 56, 1615-1620, 1996; Goldman et al., Proc. Natl. Acad. Sci. USA 95, 8795-8800, 1998; Fong et al., Cancer Res. 59, 99-106, 1999; Wedge et al., Cancer Res. 60, 970-975, 2000; Wood et al. Cancer Res. 60, 2178-2189, 2000; Siemeister et al., Cancer Res. 59, 3185-3191, 1999). Even by escalation of therapeutic doses a plateau level of therapeutic efficacy was achieved (Kim et al., Nature 362, 841-844, 1993; Wood et al. Cancer Res. 60, 2178-2189, 2000). Similar results were observed upon interference with the Angiopoietin/Tie2 receptor system (Lin et al., J. Clin. Invest. 103, 159-165, 1999; Lin et al., Proc. Natl. Acad. Sci. USA 95, 8829-8834, 1998; Siemeister et al., Cancer Res. 59, 3185-3191, 1999).

However, there is a high demand for methods that enhance the therapeutic efficacy of anti-angiogenous compounds.

Searching for methods that enhance the therapeutic efficacy of anti-angiogenic compounds, superior anti-tumor effects were observed unexpectedly upon combination of inhibition of VEGF/VEGF receptor systems and interference with biological function of Angiopoietin/Tie receptor systems. The mode of action underlying the superior effects observed may be that interference biological function of Angiopoietin/Tie receptor systems destabilizes endothelial cell-peri-endothelial cell interaction of existing mature tumor vessels and thereby sensitizes the endothelium to compounds directed against VEGF/VEGF receptor systems.

Based on this unexpected finding the present invention provides the combination of functional interference with VEGF/VEGF receptor systems and with

Angiopoietin/Tie receptor systems for inhibition of vascularization and of tumor growth.

The pharmaceutical composition consists of two components: compound I inhibits the biological activity of one or several of the VEGF/VEGF receptor systems or

5 consists of cytotoxic agents which are targeted to the endothelium via recognition of VEGF/VEGF receptor systems. Compound II interferes with the biological function of one or several of Angiopoietin/Tie receptor systems or consists of cytotoxic agents which are targeted to the endothelium via recognition of Angiopoietin/Tie receptor systems. Alternatively, compound I inhibits the biological
10 activity of one or several of the VEGF/VEGF receptor systems or of the Angiopoietin/Tie receptor systems and compound II consists of cytotoxic agents which are targeted to the endothelium via recognition of one or several of the VEGF/VEGF receptor systems or of the Angiopoietin/Tie receptor systems.

Targeting or modulation of the biological activities of VEGF/VEGF receptor

15 systems and of Angiopoietin/Tie receptor systems can be performed by

(a) compounds which inhibit receptor tyrosine kinase activity,

(b) compounds which inhibit ligand binding to receptors,

(c) compounds which inhibit activation of intracellular signal pathways of the
20 receptors,

(d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,

(e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents
25 or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,

(f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.


30 A compound comprised by compositions of the present invention can be a small molecular weight substance, an oligonucleotide, an oligopeptide, a recombinant protein, an antibody, or conjugates or fusionproteins thereof. An example of an inhibitor is a small molecular weight molecule which inactivates a receptor tyrosine

kinase by binding to and occupying the catalytic site such that the biological activity of the receptor is decreased. Kinase inhibitors are known in the art (Sugen: SU5416, SU6668; Fong et al. (1999), *Cancer Res.* 59, 99-106; Vajkoczy et al., *Proc. Am. Associ. Cancer Res. San Francisco* (2000), Abstract ID 3612; Zeneca: ZD4190, ZD6474; Wedge et al. (2000), *Cancer Res.* 60, 970-975; Parke-Davis PD0173073, PD0173074; Johnson et al., *Proc. Am. Associ. Cancer Res., San Francisco* (2000), Abstract ID 3614; Dimitroff et al. (1999), *Invest. New Drugs* 17, 121-135). An example of an antagonist is a recombinant protein or an antibody which binds to a ligand such that activation of the receptor by the ligand is prevented. Another example of an antagonist is an antibody which binds to the receptor such that activation of the receptor is prevented. An example of an expression modulator is an antisense RNA or ribozyme which controls expression of a ligand or a receptor. An example of a targeted cytotoxic agent is a fusion protein of a ligand with a bacterial or plant toxin such as *Pseudomonas* exotoxin A, Diphtheria toxin, or Ricin A. An example of a targeted coagulation-inducing agent is a conjugate of a single chain antibody and tissue factor. Ligand-binding inhibitors such as neutralizing antibodies which are known in the art are described by Genentech (rhuMAbVEGF) and by Presta et al. (1997), *Cancer Res.* 57, 4593-4599. Ligand-binding receptor domains are described by Kendall & Thomas (1993), *Proc. Natl. Acad. Sci., U.S.A.* 90, 10705-10709; by Goldman et al. (1998) *Proc. Natl. Acad. Sci., U.S.A.* 95, 8795-8800 and by Lin et al. (1997), *J. Clin. Invest.* 100, 2072-2078. Further, dominant negative receptors have been described by Millauer et al. (1994), *Nature* 367, 567-579. Receptor blocking antibodies have been described by Imclone (c-p1C11, US 5,874,542). Further known are antagonistic ligand mutants (Siemeister et al. (1998), *Proc. Natl. Acad. Sci., U.S.A.* 95, 4625-4629). High affinity ligand- or receptor binding oligo nucleotides have been described by NeXstar (NX-244) and Drolet et al. (1996), *Nat. Biotech* 14, 1021-1025. Further, small molecules and peptides have been described.

Expression regulators have been described as anti-sense oligo nucleotides and as ribozymes (RPI, Angiozyme™, see RPI Homepage).

Examples for delivery-/Targeting-Systems have been described as ligand/
 antibody-toxin-fusion-proteins or conjugates (Arora et al. (1999), Cancer Res. 59,
 183-188 and Olson et al. (1997), Int. J. Cancer 73, 865-870), as endothel cell
 targeting of liposomes (Spragg et al. (1997), Prog. Natl. Acad. Sci, U.S.A94, 8795-
 5 8800, and as endothel cell targeting plus coagulation-induction (Ran et al., (1998),
 Cancer Res. 58, 4646-4653).

10 Small molecules which inhibit the receptor tyrosine kinase activity are for example
 molecules of general formula I



I,

in which


r has the meaning of 0 to 2,

n has the meaning of 0 to 2;

R₃ und R₄ a) each independently from each other have the meaning
 of lower alkyl,

9

b) together form a bridge of general partial formula II;




5

m

wherein the binding is via the two terminal C- atoms, and has the meaning of 0 to 4; or

c) together form a bridge of partial formula III

10



15

wherein one or two of the ring members T_1, T_2, T_3, T_4 has the meaning of nitrogen, and each others have the meaning of CH, and the bining is via the atoms T_1 and T_4 ;

G

20

has the meaning of $C_1 - C_6$ - alkyl, $C_2 - C_6$ - alkylene or $C_2 - C_6$ - alkenylene; or $C_2 - C_6$ - alkylene or $C_3 - C_6$ - alkenylene, which are substituted with acyloxy or hydroxy; $-CH_2-O-$, $-CH_2-S-$, $-CH_2-NH-$, $-CH_2-O-CH_2-$, $-CH_2-S-CH_2-$, $-CH_2-NH-CH_2$, oxa ($-O-$), thia ($-S-$) or imino ($-NH-$),

A, B, D, E and T

25

independently from each other have the meaning of N or CH , with the provisio that not more than three of these Substituents have the meaning of N,

Q has the meaning of lower alkyl, lower alkyloxy or halogene,
R₁ and R₂ independently from each other have the meaning of H or
lower alkyl,

X has the meaning of imino, oxa or thia;

5 Y has the meaning of hydrogene, unsubstituted or substituted
aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and

Z has the meaning of amino, mono- or disubstituted amino,
halogen, alkyl, substituted alkyl, hydroxy, etherificated or
esterificated hydroxy, nitro, cyano, carboxy, esterificated
10 carboxy, alkanoyl, carbamoyl, N-mono- or N, N- disubstituted
carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio,
phenyl-lower-alkyl-thio, alkyl-phenyl-thio, phenylsulfinyl,
phenyl-lower-alkyl-sulfinyl, alkylphenylsulfinyl, phenylsulfonyl,
phenyl-lower-alkan-sulfonyl, or alkylphenylsulfonyl, whereas, if
15 more than one rest Z is present ($m \geq 2$), the substituents Z are
equal or different from each other, and wherein the bonds
marked with an arrow are single or double bonds; or an N-
oxide of said compound, wherein one ore more N-atoms carry
an oxygene atom, or a salt thereof.

20

A preferred salt is the salt of an organic acid, especially a succinate.

These compounds can preferentially be used as compound I or II in the inventive
pharmaceutical composition.


25

Compounds which stop a tyrosin phosphorylation, or the persistent angiogenese,
respectively, which results in a prevention of tumor growth and tumor spread, are
for example

anthranyl acid derivatives of general formula IV

30

11



IV


in which

A has the meaning of group =NR²,

5 W has the meaning of oxygen, sulfur, two hydrogen atoms or the group =NR⁸,

Z has the meaning of the group =NR¹⁰ or =N-, -N(R¹⁰)- (CH₂)_q-, branched or unbranched C₁₋₆-Alkyl or is the group


10



15

or A, Z and R¹ together form the group

20



m, n and o

q

R_a, R_b, R_c, R_d, R_e, R_f

has the meaning of 0 – 3,

has the meaning of 1 – 6,

independently from each other have the meaning of hydrogen, C₁₋₄ alkyl or the group =NR¹⁰, and/ or R_a and/ or R_b together with R_c and or R_d or R_c together with R_e and/ or R_f form a bound, or up to two of the groups R_a-R_f form a bridge with each up to 3 C-atoms with R¹ or R²,

has the meaning of group =NR⁹ or =N-,has the meaning of group -(CH₂)_p,

has the meaning of integer 1-4,

has the meaning of unsubstituted or optionally substituted with one or more of halogene, C₁₋₆-alkyl, or C₁₋₆-alkyl or C₁₋₆-alkoxy, which is

optionally substituted by one or more of halogen, or is unsubstituted or substituted aryl or

heteroaryl,

has the meaning of hydrogen or C₁₋₆-alkyl, or


form a bridge with up to 3 ring atoms with R_a-R_f together with Z or R₁,

has the meaning of monocyclic or bicyclic aryl or heteroaryl which is unsubstituted or optionally substituted with one or more of für halogen, C₁₋₆-alkyl, C₁₋₆-alkoxy or hydroxy,

independently from each other have the meaning of hydrogen, halogen or C₁₋₆-alkoxy, C₁₋₆-alkyl or

R⁴, R⁵, R⁶ and R⁷


C₁₋₆-carboxyalkyl, which are unsubstituted or optionally substituted with one or more of halogen, or R⁵ and R⁶ together form the group



- 5 R⁸, R⁹ and R¹⁰ independently from each other have the meaning of hydrogen or C₁₋₆-alkyl, as well as their isomers and salts.


10 These compounds can also preferentially be used as compound I or II in the inventive pharmaceutical composition.


More preferentially compounds of general formula V




- 15 in which
R¹ has the meaning of group

20






in which R⁵ is chloro, bromo or the group -OCH₃,



in which R⁷ is -CH₃ or chloro,




in which R^8 is $-CH_3$, fluoro, chloro or $-CF_3$

in which R^4 is fluoro, chloro, bromo, $-CF_3$, $-N=C$, $-CH_3$, $-OCF_3$ or $-CH_2OH$

in which R^6 is $-CH_3$ or chloro

R^2

has the meaning of pyridyl or the group



and

R^3

has the meaning of hydrogen or fluoro, as well as their isomers and salts can be used as compound I or II in the inventive pharmaceutical composition.

These compounds have the same properties as already mentioned above under compound IV and can be used for the treatment of angiogeneous diseases.

Compositions comprise compounds of general formulars I, IV and V, alone or in combination.

The above mentioned compounds are also claimed matter within the inventive combinations.

A further example for ligand binding inhibitors are peptides and DNA sequences coding for such peptides, which are used for the treatment of angiogeneous diseases. Such peptides and DNA sequences are disclosed in Seq. ID No. 1 to 59 of the sequence protocoll. It has been shown that Seq. ID Nos. 34 and 34a are of main interest.

Claimed matter of the instant invention are therefor pharmaceutical compositions

a) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems,

5

b) comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems,

10

c) comprising one or several agents as compound I which modulates the biological function of one or several of the VEGF/VEGF receptor systems or of one or several of the Angiopoietin/ Tie receptor systems and comprising one or several agents as compound II which are targeted to the endothelium,

15

d) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems,

20

e) comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems,

25

f) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems,

30

g) comprising one or several agents as compound I which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems and

h) comprising one or several agents which interfere with both the function of one or several of the VEGF/VEGF receptor systems and the function of one or several of the Angiopoietin/Tie receptor systems.

5

For a sequential therapeutical application the inventive pharmaceutical compositions can be applied simultaneously or separately .

The inventive compositions comprise as compound I or as compound II at least one of

10

- a) compounds which inhibit receptor tyrosine kinase activity,
- b) compounds which inhibit ligand binding to receptors,
- c) compounds which inhibit activation of intracellular signal pathways of the receptors,
- 15 d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of
- 20 VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

20

These compositions are also claimed matter of the present invention.

25

Also claimed matter of the present invention are pharmaceutical compositions which comprise as compound I and/ or II at least one of Seq. ID Nos. 1-59.

Of most value are pharmaceutical compositions, which comprise as compound I and/ or II Seq. ID Nos. 34a und pharmaceutical compositions according to claims

30 which comprise as compound I and/ or II at least one of sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate.

30

Further preferred matter of the present invention are pharmaceutical compositions, which comprise as compound I and/ or II at least one small molecule of general formula I, general formula IV and/ or general formula V.

- 5 The most preferred compound which can be used as compound I or II in the inventive composition is (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate.

Therefore, claimed matter of the present invention are also pharmaceutical compositions, which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, and as compound II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, with the proviso that compound I is not identically to compound II, and most preferred pharmaceutical compositions, which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and as compound II sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate; pharmaceutical compositions, which comprise as compound I mAB 4301-42-35 and as compound II sTie2, and/ or scFv-tTF conjugate; pharmaceutical compositions, which comprise as compound I scFv-tTF conjugate and as compound II sTie2 and/ or mAB 4301-42-35; pharmaceutical compositions, which comprise as compound I L19 scFv-tTF conjugate and as compound II sTie2.

The small molecule compounds, proteins and DNA's expressing proteins, as mentioned above can be used as medicament alone, or in form of formulations for the treatment of tumors, cancers, psoriasis, arthritis, such as rheumatoide arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaukoma, kidney diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathic syndrome, transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis and damage of nerve tissues.

The treatment of the damaged nerve tissues with the inventive combination hinders the rapid formation of scars at the damaged position. Thus, there is no

scar formation before the axons communicate with each other. Therefore a reconstruction of the nerve bindings is much more easier.

Further, the inventive combinations can be used for suppression of the ascites formation in patients. It is also possible to suppress VEGF oedemas.

For the use of the inventive combinations as medicament the compounds will be formulated as pharmaceutical composition. Said formulation comprises beside the active compound or compounds acceptable pharmaceutically, organically or inorganically inert carriers, such as water, gelatine, gum arabic, lactose, starch, magnesium stearate, talcum, plant oils, polyalkylene glycols, etc. Said pharmaceutical preparations can be applied in solid form, such as tablets, pills, suppositories, capsules, or can be applied in fluid form, such as solutions, suspensions or emulsions.

If necessary, the compositions additionally contain additives, such as

preservatives, stabilizer, detergents or emulgators, salts for alteration of the osmotic pressure and/ or buffer.

These uses are also claimed matter of the instant invention, as well as the formulations of the active compounds

For parenteral application especially injectable solutions or suspensions are suitable, especially hydrous solutions of the active compound in polyhydroxyethoxylated castor-oil are suitable.

As carrier also additives can be used, such as salts of the gallic acid or animal or plant phospholipids, as well as mixtures thereof, and liposomes or ingredients thereof.

For oral application especially suitable are tablets, pills or capsules with talcum and/ or hydrocarbon carriers or binders, such as lactose, maize or potato starch. The oral application can also be in form of a liquid, such as juice, which optionally contains a sweetener.

The dosis of the active compound differs depending on the application of the compound, age and weight of the patient, as well as the form and the progress of the disease.

The daily dosage of the active compound is 0,5-1000 mg, especially 50-200 mg.

The dosis can be applied as single dose or as two or more daily dosis.

These formulations and application forms are also part of the instant invention.

Combined functional interference with VEGF/VEGF receptor systems and with
5 Angiopoietin/Tie receptor systems can be performed simultaneously, or in
sequential order such that the biological response to interference with one
ligand/receptor system overlaps with the biological response to interference with a
second ligand/receptor system. Alternatively, combined functional interference
10 with VEGF/VEGF receptor systems or with Angiopoietin/Tie receptor systems and
targeting of cytotoxic agents via VEGF/VEGF receptor systems or via
Angiopoietin/Tie receptor systems can be performed simultaneously, or in
sequential order such that the biological response to functional interference with a
ligand/receptor system overlaps in time with targeting of cytotoxic agents.

15 The invention is also directed to a substance which functional interferes with both
VEGF/VEGF receptor systems and Angiopoietin/Tie receptor systems, or which
are targeted via both VEGF/VEGF receptor systems and Angiopoietin/Tie receptor
systems.

20 VEGF/VEGF receptor systems include the ligands VEGF-A, VEGF-B, VEGF-C,
VEGF-D, PlGF, and the receptor tyrosine kinases VEGF-R1 (Flt1), VEGF-R2
(KDR/Flk1), VEGF-R3 (Flt4), and their co-receptors (i.e. neuropilin-1).
Angiopoietin/Tie receptor systems include Ang1, Ang2, Ang3/Ang4, and
angiopoietin related polypeptides which bind to Tie1 or to Tie2, and the receptor
25 tyrosine kinases Tie1 and Tie2.

Pharmaceutical compositions of the present invention can be used for medicinal
purposes. Such diseases are, for example, cancer, cancer metastasis,
angiogenesis including retinopathy and psoriasis. Pharmaceutical compositions of
30 the present invention can be applied orally, parenterally, or via gene therapeutic
methods.

Therefor the present invention also concerns the use of pharmaceutical
compositions for the production of a medicament for the treatment of tumors,

cancers, psoriasis, arthritis, such as rheumatoide arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaukoma, kidney diseases, such as glomerulonephritis, diabetic nephropathie, malignant nephrosclerosis, thrombotic microangiopathic syndrome, transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis, damage of nerve tissues, suppression of the ascites formation in patients and suppression of VEGF oedemas.

The following examples demonstrate the feasibility of the disclosed invention, without restricting the invention to the disclosed examples.

5 **Example 1**

Superior effect on inhibition of tumor growth via combination of inhibition of the VEGF A/VEGF receptor system together with functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention was demonstrated in an A375v human melanoma xenograft model.

10

Human melanoma cell line A375v was stably transfected to overexpress the extracellular ligand-neutralizing domain of human Tie2 receptor tyrosine kinase (sTie2; compound II) (Siemeister et al., Cancer Res. 59, 3185-3191, 1999). For control, A375v cells were stably transfected with the empty expression vector (A375v/pCEP). Swiss *nu/nu* mice were s.c. injected with 1×10^6 transfected
15 A375v/sTie2 or A375v/pCEP tumor cells, respectively. Animals receiving compound I were treated for up to 38 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60,
20 2178-2189, 2000). Various modes of treatment are described in Table 1. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 1

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

- 5 Tumors derived from A375v/pCEP control cells reached a size of approx. 250 mm² (mean area) within 24 days (Figure 1) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) or separate interference with Angiopoietin/Tie2 receptor system by means of
- 10 expression of sTie2 (compound II, treatment group 3) delayed growth of tumors to a size of approx. 250 mm² to 31 days, respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of interference with the VEGF/VEGF receptor system by means of the kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I + compound II, treatment group 4) delayed growth of the
- 15 tumors to a size of approx. 250 mm² to 38 days.

This result clearly demonstrates the superior effect of a combination of interference with the VEGF-A/VEGF receptor system and the Angiopoietin/Tie2 receptor system over separate modes of intervention.

Example 2

Combination of functional interference with the Angiopoietin/Tie2 receptor system and neutralization of VEGF-A is superior to separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated twice weekly over a period of time of 4 weeks with intraperitoneal doses of 200 µg of the VEGF-A-neutralizing monoclonal antibody (mAb) 4301-42-35 (Schlaeppli et al., J. Cancer Res. Clin. Oncol. 125, 336-342, 1999). Various modes of treatment are described in Table 2. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 2

treatment group	mode of treatment	
	mAb 4301-42-35 (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 2) without treatment (group 1). Tumors treated with the VEGF-A-neutralizing mAb 4301-42-35 (compound I, treatment group 2) grew to a volume of approx. 450 mm³ within 28 days. Interference with

Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm², respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and neutralizing of VEGF-A by means of the mAb 4301-42-35 (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 250 mm³ within 28 days.

The superior effect of a combination of neutralization of VEGF-A and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown.

Example 3

Combination of functional interference with the Angiopoietin/Tie2 receptor system and targeting of a coagulation-inducing protein via the VEGF/VEGF receptor system is superior to separate modes of intervention in inhibition of tumor growth.

5

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. A single chain antibody (scFv) specifically recognizing the human VEGF-A/VEGF receptor I complex (WO 99/19361) was expressed in *E. coli* and conjugated to coagulation-inducing

10

recombinant human truncated tissue factor (tTF) by methods described by Ran et al. (Cancer Res. 58, 4646-4653, 1998). When tumors reached a size of approx. 200 mm³ animals receiving compound I were treated on day 0 and on day 4 with intravenous doses of 20 µg of the scFv-tTF conjugate. Various modes of treatment are described in Table 3. Animals were sacrificed for ethical reasons

15

when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 3

treatment group	mode of treatment	
	scFv-tTF conjugate (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

20

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 3) without treatment (group 1). Tumors treated with the coagulation-inducing tTF targeted to the VEGF-A/VEGF receptor I complex via the scFv-tTF conjugate (compound I, treatment group 2) grew to a volume of approx. 500 mm³ within 28 days. Interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm², respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of targeting the VEGF receptor complex (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 300 mm³ within 28 days.

The superior effect of a combination of targeting of the coagulation-inducing tTF to the VEGF-A/VEGF receptor I complex and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown. Similar effects can be expected upon targeting of cytotoxic agents to VEGF/VEGF receptor systems.

Example 4

Combination of functional interference with the VEGF/VEGF receptor system and targeting of a coagulation-inducing protein via the VEGF/VEGF receptor system is superior to separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated for up to 28 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Compound II consists of a single chain antibody (scFv) specifically recognizing the human VEGF-A/VEGF receptor I complex (WO 99/19361) which was expressed in *E. coli* and conjugated to coagulation-inducing recombinant human truncated tissue factor (tTF) by methods described by Ran et al. (Cancer Res. 58, 4646-4653, 1998). When tumors reached a size of approx. 200 mm³ animals receiving compound II were treated on day 0 and on day 4 with intravenous doses of 20 µg of the scFv-tTF conjugate. Various modes of treatment are described in Table 4. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 4

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I)	scFv-tTF conjugate (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/pCEP	-	+
Group 4: A375v/pCEP	+	+

- 5 Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 4) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) resulted in a reduction of the tumor volumes to approx. 550 mm³. Tumors treated with the
- 10 coagulation-inducing tTF targeted to the VEGF-A/VEGF receptor I complex via the scFv-tTF conjugate (compound II, treatment group 3) grew to a volume of approx. 500 mm³ within 28 days. Combination of inhibition of VEGF receptor tyrosine kinase by means of (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and of targeting the VEGF receptor complex
- 15 (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 400 mm³ within 28 days.

The superior effect of a combination of targeting of the coagulation-inducing tTF to the VEGF-A/VEGF receptor I complex and functional interference with the

20 VEGF/VEGF receptor system over separate modes of intervention is clearly

shown. Similar effects can be expected upon targeting of cytotoxic agents to Angiopoietin/Tie receptor systems.

Example 5

Combination of functional interference with the Angiopoietin/Tie2 receptor system and endothelium-specific targeting of a coagulation-inducing protein is superior to separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. A fusion protein (L19 scFv-tTF) consisting of L19 single chain antibody specifically recognizing the oncofoetal ED-B domain of fibronectin and the extracellular domain of tissue factor was expressed in *E. coli* as described by Nilsson et al. (Nat. Med., in press). Further, L19 scFv-tTF data have been represented by D. Neri and F. Nilsson (Meeting "Advances in the application of monoclonal antibodies in clinical oncology", Samos, Greece, 31. May-2. June 2000). When tumors reached a size of approx. 200 mm³ animals receiving compound I were treated with a single intravenous dose of 20 µg of L19 scFv-tTF in 200 µl saline. Various modes of treatment are described in Table 5. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 5

treatment group	mode of treatment	
	L19 scFv-tTF (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 5) without treatment (group 1). Tumors treated with the coagulation-inducing L19 scFv-tTF (compound I, treatment group 2) grew to a volume of approx. 450 mm³ within 28 days. Interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm², respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of targeting the endothelium with L19 scFv-tTF (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 250 mm³ within 28 days.

The superior effect of a combination of targeting of L19 scFv-tTF to the endothelium and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown.

Example 6

Combination of functional interference with the VEGF/VEGF receptor system and endothelium-specific targeting of a coagulation-inducing protein is superior to
5 separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated for up to 28 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-
10 Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Compound II consists of L19 scFv-tTF fusion protein as described in example 5. When tumors reached a size of approx. 200 mm³ animals receiving compound II were treated with a single intravenous dose of 20 µg of L19 scFv-tTF in 200 µl saline. Various modes of
15 treatment are described in Table 6. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 6

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthal-azin-1-yl]ammonium hydrogen succinate (compound I)	L19 scFv-tTF (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/pCEP	-	+
Group 4: A375v/pCEP	+	+

5

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 6) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) resulted in a reduction of the tumor volumes to approx. 550 mm³. Tumors treated with the coagulation-inducing L19 scFv-tTF targeted to the endothelium (compound II, treatment group 3) grew to a volume of approx. 450 mm³ within 28 days. Combination of inhibition of VEGF receptor tyrosine kinase by means of (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and of targeting the VEGF receptor complex (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 200 mm³ within 28 days.

10

15

The superior effect of a combination of targeting of L19 scFv-tTF to the endothelium and functional interference with the VEGF/VEGF receptor system over separate modes of intervention is clearly shown.

5

10

Description of the figures

Fig. 1 shows the superior effect of combination of interference with VEGF/VEGF receptor system by means of a specific tyrosine kinase inhibitor and with the Angiopoietin/Tie2 receptor system by means of a soluble receptor domain on inhibition of tumor growth (treatment modes of groups 1-4 are given in Table 1).

The abbreviations have the following meaning:

	mock, con.	=	treatment group 1
	mock+VEGF-A	=	treatment group 2
10	sTIE2-cl13	=	treatment group 3
	sTIE2-cl13+VEGF-A	=	treatment group 4

Fig. 2 shows the superior effect on tumor growth inhibition of combination of VEGF-neutralization and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 2).

Fig. 3 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing tTF to the VEGF/VEGF receptor I complex via a scFv-tTF conjugate and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 3).

Fig. 4 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing tTF to the VEGF/VEGF receptor I complex via a scFv-tTF conjugate and functional interference with VEGF/VEGF receptor system by means of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate over separate modes of intervention (treatment modes of groups 1-4 are given in Table 4).

Fig. 5 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing L19 scFv-tTF fusion protein to the endothelium and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 5).

Fig. 6 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing L19 scFv-tTF fusion protein to the endothelium and functional interference with VEGF/VEGF receptor system by means of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate over separate modes of intervention (treatment modes of groups 1-4 are given in Table 6).

CLAIMS

1. Pharmaceutical compositions comprising one or several agents as compound I
which modulate the biological function of one or several of the VEGF/VEGF
5 receptor systems, and comprising one or several agents as compound II which
modulate the biological function of one or several of the Angiopoietin/Tie
receptor systems.
2. Pharmaceutical compositions comprising one or several agents as compound I
10 which are targeted to the endothelium via one or several of the VEGF/VEGF
receptor systems, and comprising one or several agents as compound II which
modulate the biological function of one or several of the Angiopoietin/Tie
receptor systems.
- 15 3. Pharmaceutical compositions comprising one or several agents as compound I
which modulates the biological function of one or several of the VEGF/VEGF
receptor systems or of one or several of the Angiopoietin/ Tie receptor systems
and comprising one or several agents as compound II which are targeted to
the endothelium.
- 20 4. Pharmaceutical compositions comprising one or several agents as compound I
which modulate the biological function of one or several of the VEGF/VEGF
receptor systems, and comprising one or several agents as compound II which
are targeted to the endothelium via one or several of the Angiopoietin/Tie
25 receptor systems.
5. Pharmaceutical compositions comprising one or several agents as compound I
which are targeted to the endothelium via one or several of the VEGF/VEGF
receptor systems, and comprising one or several agents as compound II which
30 are targeted to the endothelium via one or several of the Angiopoietin/Tie
receptor systems.
6. Pharmaceutical compositions comprising one or several agents as compound
I which modulate the biological function of one or several of the VEGF/VEGF

receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems.

- 5 7. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems.

10

8. Pharmaceutical compositions comprising one or several agents which interfere with both the function of one or several of the VEGF/VEGF receptor systems and the function of one or several of the Angiopoietin/Tie receptor systems.

- 15 9. Pharmaceutical compositions according to claims 1-8 which are intended for simultaneous or separate sequential therapeutical application.

10. Pharmaceutical compositions according to claims 1-8 which comprise as compound I at least one of

20

- a) compounds which inhibit receptor tyrosine kinase activity,
- b) compounds which inhibit ligand binding to receptors,
- c) compounds which inhibit activation of intracellular signal pathways of the receptors,

25

- d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,

30

- f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

11. Pharmaceutical compositions according to claims 1-8 which comprise as compound II at least one of

- g) compounds which inhibit receptor tyrosine kinase activity,
- h) compounds which inhibit ligand binding to receptors,
- 5 i) compounds which inhibit activation of intracellular signal pathways of the receptors,
- j) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- 10 k) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- 15 l) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.


12. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II at least one of Seq. ID Nos. 1-59.

13. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II Seq. ID Nos. 34a

14. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II at least one of sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTFconjugate.

15. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II at least one small molecule of general formula I

41



I,

in which


5

r has the meaning of 0 to 2,
n has the meaning of 0 to 2;

 R_3 und R_4

- a) each independently from each other have the meaning of lower alkyl,
b) together form a bridge of general partial formula II,

10



II,


15

wherein the binding is via the two terminal C- atoms,
and

m has the meaning of 0 to 4; or

- c) together form a bridge of partial formula III

20



has wherein one or two of the ring members T_1, T_2, T_3, T_4 the meaning of nitrogen, and each others have the meaning of CH, and the bining is via the atoms T_1 and T_4 ;

5 G has the meaning of $C_1 - C_6$ - alkyl, $C_2 - C_6$ - alkylene or $C_2 - C_6$ - alkenylene; or $C_2 - C_6$ - alkylene or $C_3 - C_6$ - alkenylene, which are substituted with acyloxy or hydroxy; $-CH_2-O-$, $-CH_2-S-$, $-CH_2-NH-$, $-CH_2-O-CH_2-$, $-CH_2-S-CH_2-$, $-CH_2-NH-CH_2$, oxa ($-O-$), thia ($-S-$) or imino ($-NH-$),

10 A, B, D, E and T independently from each other have the meaning of N or CH, with the provisio that not more than three of these Substituents have the meaning of N,

15 Q has the meaning of lower alkyl, lower alkyloxy or halogene,

R_1 and R_2 independently from each other have the meaning of H or lower alkyl,

X has the meaning of imino, oxa or thia;

20 Y has the meaning of hydrogen, unsubstituted or substituted aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and

Z has the meaning of amino, mono- or disubstituted amino, halogen, alkyl, substituted alkyl, hydroxy, etherificated or esterificated hydroxy, nitro, cyano, carboxy, esterificated carboxy, alkanoyl, carbamoyl, N-mono- or N, N- disubstituted carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio, phenyl-lower-alkyl-thio, alkyl-phenyl-thio, phenylsulfinyl, phenyl-lower-alkyl-sulfinyl, alkylphenylsulfinyl, phenylsulfonyl, phenyl-lower-alkan-sulfonyl, or alkylphenylsulfonyl,


25
30

whereas, if more than one rest Z is present ($m \geq 2$), the substituents Z are equal or different from each other, and wherein the bonds marked with an arrow are single

or double bonds; or an N-oxide of said compound,
 wherein one or more N-atoms carry an oxygen atom,
 or a salt thereof,

and/or a compound of general formula IV

5




in which

A has the meaning of group =NR²,

10 W has the meaning of oxygen, sulfur, two hydrogen atoms
 or the group =NR⁸,

Z has the meaning of the group =NR¹⁰ or =N-, -N(R¹⁰)-
 (CH₂)_q-, branched or unbranched C₁₋₆-Alkyl or is the
 group


15



or A, Z and R¹ together form the group

20

44



m, n and o

has the meaning of 0 – 3,

q

has the meaning of 1 – 6,

 $R_a, R_b, R_c, R_d, R_e, R_f$

independently from each other have the meaning of hydrogen, C_{1-4} alkyl or the group $=NR^{10}$, and/or R_a and/or R_b together with R_c and/or R_d or R_c together with R_e and/or R_f form a bound, or up to two of the groups R_a-R_f form a bridge with each up to 3 C-atoms with R^1 or R^2 ,

X

has the meaning of group $=NR^9$ or $=N-$,

Y

has the meaning of group $-(CH_2)_p$,

p

has the meaning of integer 1-4,

 R^1

has the meaning of unsubstituted or optionally substituted with one or more of halogene, C_{1-6} -alkyl, or C_{1-6} -alkyl or C_{1-6} -alkoxy, which is optionally substituted by one or more of halogen, or is unsubstituted or substituted aryl or heteroaryl,

 R^2


has the meaning of hydrogen or C_{1-6} -alkyl, or form a bridge with up to 3 ring atoms with R_a-R_f together with Z or R_1 ,

 R^3

has the meaning of monocyclic or bicyclic aryl or heteroaryl which is unsubstituted or optionally

R^4, R^5, R^6 and R^7


substituted with one or more of für halogen, C_{1-6} -alkyl, C_{1-6} -alkoxy or hydroxy, independently from each other have the meaning of hydrogen, halogene or C_{1-6} -alkoxy, C_{1-6} -alkyl or C_{1-6} -carboxyalkyl, which are unsubstituted or optionally substituted with one or more of halogene, or R^5 and R^6 together form the group



R^8, R^9 and R^{10}

independently from each other have the meaning of hydrogen or C_{1-6} -alkyl, as well as their isomers and salts,

and/ or a compound of general formula V




V,

in which


R^1 has the meaning of group

46




in which R^5 is chloro, bromo or the group $-OCH_3$,

5



in which R^7 is $-CH_3$ or chloro,




in which R^8 is $-CH_3$, fluoro, chloro or $-CF_3$

in which R^4 is fluoro, chloro, bromo, $-CF_3$, $-N=C$, $-CH_3$, $-OCF_3$ or $-CH_2OH$

in which R^6 is $-CH_3$ or chloro

R^2

has the meaning of pyridyl or the group



and

R^3

has the meaning of hydrogen or fluoro, as well as their isomers and salts.

16. Pharmaceutical compositions according to claim 15 which comprise as compound I and/ or II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate

17. Pharmaceutical compositions according to claims 1-16 which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, and as compound II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, with the proviso that compound I is not identically to compound II.

18. Pharmaceutical compositions according to claims 1-17 which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium

hydrogen succinate and as compound II sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate.


19. Pharmaceutical compositions according to claims 1-17 which comprise as
5 compound I mAB 4301-42-35 and as compound II sTie2, and/ or scFv-tTF conjugate.

20. Pharmaceutical compositions according to claims 1-17 which comprise as
10 compound I scFv-tTF conjugate and as compound II sTie2 and/ or mAB 4301-42-35.

21. Pharmaceutical compositions according to claims 1-17 which comprise as
compound I L19 scFv-tTF conjugate and as compound II sTie2.

15 22. Use of pharmaceutical compositions according to claims 1-21, for the production of a medicament for the treatment of tumors, cancers, psoriasis, arthritis, such as rheumatoide arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaukoma, kidney diseases, such as glomerulonephritis, diabetic nephropathie, malignant
20 nephrosclerosis, thrombic microangiopathic syndrome, transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis, damage of nerve tissues, suppression of the ascites formation in patients and suppression of VEGF oedemas.

25

**Fig. 1**




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6

Sequence Identifier

5

<110> Schering Aktiengesellschaft

10

<120> Combinations and compositions which interfere with VEGF/ VEGF and angiopoietin/ Tie receptor function and their use II

<130> 51867AEPM1XX00-P

15

<140>

<141>

<160> 59

20

<210> 1

<211> 1835

<212> DNA

<213> Human

25

<400> 1

30

```

ttttacagtt  ttccttttct  tcagagttta  ttttgaattt  tcattttttg  ataaccaagc  60
agctctttta  gaagaatgca  cagaagagtc  attctggcac  ttttggatag  tacataagat  120
tttctttttt  tttttttaat  tttttttaat  agtcacattc  agctcgcttg  ctcaaaccag  180
actcccacat  tgggtgagca  agatgagccc  ataggattcc  agagttaata  cgtaaccgta  240
tatacaaaca  gccaaaaaac  cataatggtg  ccacagggat  ggagcagggg  aggggcatctc  300
taacgtgtcc  tctagtctat  ctctgctaaa  cagaaccac  gttacacatg  ataactagag  360
agcacactgt  gttgaaaacg  ggatgctgac  cccaaatggc  acttggcagc  atgcagttta  420
aagcaaaaga  gacatccttt  aataactgta  taaaatccag  gcagttccat  taaaggggtt  480
aagaaaacca  acaacaacaa  aaagcgaggg  actgtctggt  gtcactgtca  aaaaggcact  540
tggagttaat  gggaccagga  ttggaggact  cttagctgat  acagatttca  gtacgatttc  600
attaaaaggc  ttggatgtta  agagaggaca  ctgagcgggt  cctgaaggga  gacgctgaga  660
tggaccgctg  agaagcggaa  cagatgaaca  caaagggaatc  aaatctttac  aaccaaaattg  720
catttaagcg  acaacaaaaa  aaggcaaac  caaaacgca  acctaacca  agcaaaatct  780
aagcaaaatc  agacaacgaa  gcagcgatgc  atagctttcc  tttgagagaa  cgcataacctt  840
gagacgctac  gtgccaacct  aagttctcaa  cgacagcttc  acagtaggat  tattgtgata  900
aaaatgactc  aagcgatgca  aaaagtttca  tctgttccca  gaatccgagg  gagaactgag  960
gtgatcggtt  gagcatagcg  acatcacgtg  cggtttctta  atgtccctgg  tggcgggatac  1020
gccgagtcct  cggaaggaca  tctggacacc  actttcagcc  acctccttgc  aggggacgaca  1080
tccgcaaaag  tcatccttta  ttccgagtaa  taactttaat  tcctttctaa  catttacacg  1140
gcaaacagga  atgcagtaaa  cgtccacgtc  cgtcccacgg  ctgggctgcc  gttccgtttc  1200
ctccacgaac  gggtaacgac  ttccatgaga  aaggatattt  ggcaatttta  tattccacag  1260
tcagggtggg  ctgcatagc  tcatttaatg  ttaaagccca  tcaggggcct  ctctcccggt  1320
ttctgccagg  ggcttttctt  gtcttctcct  tggcgagctc  gtgggcagat  cttctctggg  1380
gggggctggc  tgctggctcc  gagggggcat  ccgcagtcgc  tctggctcgc  tcctcctgca  1440
ggctgggcag  ctggccacca  cttctccgac  tcgaccctc  caacaagcat  cgcagggcac  1500
tgctcctcgg  ggtacagacc  gtggtccac  attcgctacc  actctgttcc  acgtcatcca  1560
ggtacacgag  ctgctgttag  gccgtgctgt  ctggggctcg  aggtcttttc  tgctgggtgt  1620
cttggacggg  cgggtagttc  tgctgcagag  acaaagcatc  tccccttccc  ttccgggctg  1680
atthttggtc  attcatactc  acgccagagt  ccaaaactgg  atcattactt  ccgttccttc  1740
cagctctttg  gagaatcaat  gtatgaatgt  ctaacctgac  cgttggacct  gccatccaag  1800
gagacgaacc  acgcccgggg  gtgcggaagc  ggcct

```

60

<210> 2

<211> 581

<212> DNA

<213> Human

<400> 2

5 gttctagatt gttttattca gtaattagct ctttaagaccc ctggggcctg tgctaccag 60
 acactaaca cagtctctat ccagttgctg gttctgggtg acgtgatctc cccatcatga 120
 tcaacttact tccgtgtggc cattagggaa gtggtgacct cgggagctat ttgectgttg 180
 agtgcacaca cctggaaaca tactgctctc attttttcat ccacatcagt gagaaatgag 240
 tggcccgtta gcaagatata actatgcaat catgcaacaa agctgcctaa taacatttca 300
 10 tttattacag gactaaaagt tcattattgt ttgtaaagga tgaattcata acctctgcag 360
 agttatagtt catacacagt tgatttccat ttataaaggc agaaagtcct tgttttctct 420
 aaatgtcaag ctttgactga aaactcccgt ttttccagtc actggagtgt gtgcgtatga 480
 aagaaaatct ttagcaatta gatgggagag aagggaata gtacttgaaa tgtaggcct 540
 cacctcccca tgacatcctc catgagcctc ctgatgtagt g

15 <210> 3
 <211> 516
 <212> DNA
 <213> Human

<400> 3

25 tagagatggt ggttgatgac ccccgggatc tggagcagat gaatgaagag tctctggaag 60
 tcagcccaga catgtgcac tacatcacag aggacatgct catgtcgcgg aacctgaatg 120
 gacactctgg gttgattgtg aaagaaattg ggtcttccac ctcgagctct tcagaaacag 180
 ttgttaagct tctgtggccag agtactgatt ctcttccaca gactatatgt cggaaaccaa 240
 agacctccac tgatcgacac agcttgagcc tcatgacat cagactttac cagaaagact 300
 tcttgcgcat tgcaggctctg tgtcaggaca ctgctcagag ttacaccttt ggatgtggcc 360
 atgaactgga tgaggaaagg ctctattgca acagttgctt ggcccagcag tgcataca 420
 tccaagatgc ttttccagtc aaaagaacca gcaataactt ttctctggat ctcaactcatg 480
 30 atgaagtcc agagtttgtt gtgtaaagtc cgtctg

<210> 4
 <211> 1099
 <212> DNA
 35 <213> Human

<400> 4

40 cccacaacac agggggccctg aaacacgcca gcctctcctc tgtggtcagc ttggcccagt 60
 cctgctcact ggatcacagc ccattgtagg tggggcatgg tggggatcag ggcccctggc 120
 ccacggggag gtagaagaag acctggtccg tgtaagggtc tgagaagggt ccctgggtcg 180
 ggggtgcgtc ttggccttgc cgtgccctca tcccccggt gaggcagcga cacagcaggt 240
 gcaccaactc cagcaggtta agcaccaggg agatgagtcc aaccaccaac atgaagatga 300
 45 tgaagatggt cttctccgtg gggcgagaga caaagcagtc cacgagtag gggcagggtg 360
 ctgcctggca cacaacacg ggctccatgg tccagcgtta caggcgccac tggccataga 420
 ggaagcctgc ctctagcaca ctcttgca gaacactggc gacatagggt cccatcagtg 480
 ctccgcggat gcgcaggcga ccatcttctg ccaccgagat cttggccatc tgacgctcta 540
 cggccgcccag cggccgctcc acctgtgggt ccttggccgg cagtggccgc agctccccct 600
 cttctgccc cagccgctct tctgcgcgag acaggtaaat gacatggccc aggtagacca 660
 50 ggggtgggtg gctgacgaag aggaactgca gcaccagta gcggatgtgg gagatgggga 720
 aggcctggtc atagcagacg ttggtgcagc ctggctgggc cgtgttacac tcgaaatctg 780
 actgctcgtc accccacact gactcgccgg ccaggcccag gatgaggatg cggaagatga 840
 agagcaccgt cagccagatc ttacccaacca cggctcagtg ctccctggacc tggctcagca 900
 acttctccac gaagccccag tcacccatgg ctcccgggcc tccgtcggca aggagacaga 960
 55 gcacgtcagt gtgtcagcat ggcattcctc tcgttcgccc agcaacaagc ctgcaggag 1020
 gtctgccacg cccgttctac cgcctgcctg ccgggcggcc caggtggagg tggggacgat 1080
 ggccggagtg acgcccgcg

<210> 5
 60 <211> 1015
 <212> DNA
 <213> Human

<400> 5

65 gaggataggg agcctggggg caggagtgtg ggagacacag cgagactctg tctccaaaaa 60

	aaaaagtgc	ttttgaaaat	gttgaggttg	aaatgatggg	aaccaacatt	ctttggattt	120
	agtggggagc	ataatagcaa	acacccccct	ggttcgcaca	tgtacaggaa	tgggacccag	180
	ttggggcaca	gccatggact	tccccgccct	ggaatgtgtg	gtgcaaagt	gggccagggc	240
5	ccagacccaa	gaggagagg	tggtccgcag	acacccccgg	atgtcagcat	cccccgacct	300
	gccttctggc	ggcacctccc	gggtgctgtg	ttgagtcagc	aggcatgggg	tgagagcctg	360
	gtatatgtctg	ggaacaggg	gtctcacacg	agcgttccctc	cttcagccct	gacttggggc	420
	atgcaccccc	tctcccccaa	acacaaacaa	gcactttctcc	agtatgggtgc	caggacaggt	480
	gtcccttcag	tctctgtggt	atgacctcaa	gtcctacttg	ggccctgcag	cccagcctgt	540
10	gttgtaacct	ctgcgtcctc	aagaccacac	ctggaagatt	cttcttccct	ttgaaggaga	600
	atcatcattg	ttgcttttatc	actttctaaga	cattttgtat	ggcacggaca	agttaaacag	660
	aatgtgcttc	cctccctggg	gtctcacacg	ctccccagag	aatgcacacg	ggcccggtgca	720
	ctgggcaggg	ttctctgtag	aaccccgagg	gcttcggccc	agaccacagc	gtcttgccct	780
	gagcctagag	cagggagtc	cgaacttctg	cattcacaga	ccacctccac	aattgttata	840
15	accaaaggcc	tcctgtttctg	ttattttact	taaatcaaca	tgctattttg	ttttcactca	900
	cttctgactt	tagcctcgtg	ctgagccgtg	tatccatgca	gtcatgttca	cgtgctagtt	960
	acgtttttct	tcttacacat	gaaaataaat	gcataagtg	tagaagaaaa	aaaaa	
	<210> 6						
20	<211> 2313						
	<212> DNA						
	<213> Human						
	<400> 6						
25	ccagcagcag	cctggtggtg	agcagggagc	gtgcaccgga	cggcggggatc	gagcaaatgg	60
	gtctggccat	ggagcacgga	gggtcctacg	ctcgggcggg	gggcagctct	cggggctgct	120
	ggtattacct	gcgctacttc	ttcctcttcg	tctccctcat	ccaattcctc	atcatcctgg	180
	ggctcgtgct	cttcatggtc	tatggcaacg	tgcacgtgag	cacagagtcc	aacctgcagg	240
30	ccaccgagcg	ccgagccgag	ggcctataca	gtcagctcct	agggctcacg	gcctcccagt	300
	ccaacttgac	caaggagctc	aacttcacca	cccgcgccaa	ggatgccatc	atgcagatgt	360
	ggctgaatgc	tcgcccgagc	ctggaccgca	tcaatgccag	cttcgccag	tgccagggtg	420
	accgggtcat	ctacacgaac	aatcagaggt	acatggctgc	catcatcttg	agtgagaagc	480
	aatgcagaga	tcaattcaag	gacatgaaca	agagctgcga	tgcttctgctc	ttcatgctga	540
	atcagaagg	gaagacgctg	gaggtggaga	tagccaagga	gaagaccatt	tgactaagg	600
35	ataaggaaa	cgtgctgctg	aacaaacgcg	tggcgaggga	acagctgggt	gaatgcgtga	660
	aaaccgggga	gctgcagcac	caagagcgcc	actggccaag	gagcaactgc	aaaaggtgca	720
	agccctctgc	ctgccccctg	acaaggacaa	gtttgagatg	gaccttcgta	acctgtggag	780
	ggactccatt	atcccaacga	gcctggacaa	cctgggttac	aacctctacc	atcccctggg	840
40	ctcgggaattg	gcctccatcc	gcagagcctg	cgaccacatg	cccagcctca	tgagctccaa	900
	ggtggaggag	ctggcccggg	gcctccgggc	ggatategaa	cgcgtggccc	gcgagaactc	960
	agacctccaa	cgccagaagc	tggaaagcca	gcagggcctg	cggccagctc	aggaggcgaa	1020
	acagaagggtg	gagaaggagg	ctcaggcccc	ggaggccaag	ctccaagctg	aatgctcccg	1080
	gcagaccag	ctagcgctgg	aggagaaggc	ggtgctgcgg	aaggaaacgag	acaacctggc	1140
45	caaggagctg	gaagagaaga	agagggaggc	ggagcagctc	aggatggagc	tgcccatcag	1200
	aaactcagcc	ctggacacct	gcatacaagc	caagtgcagc	ccgatgatgc	cagtgtcaag	1260
	gcccatgggc	cctgtcccca	accccagcc	catcgaccca	gctagcctgg	aggagttcaa	1320
	gaggaagatc	ctggagtcct	agaggcccc	tgaggcatc	cctgtagccc	catccagtgg	1380
	ctgaggaggc	tccaggcctg	aggaccaagg	gatggcccga	ctcggcggtt	tgccgaggat	1440
50	gcagggatat	gctcacagcg	cccgcacaaa	ccccctcccg	ccgcccccaa	ccacccaggg	1500
	ccaccatcag	acaactccct	gcatgcacac	ccctagtacc	ctctcacacc	cgcaaccgcg	1560
	cctcacgcat	cctgcaccag	agcacacggc	cgcggagatg	acgtcacgca	agcaaccggc	1620
	ctgacgtcac	atatcacctg	ggtgatggcg	tcacgtggcc	atgtagacgt	cacgaagaga	1680
	tatagcgatg	gcgtcgtgca	gatgcagcac	gtcgcacaca	gacatgggga	acttggcatg	1740
	acgtcacacc	gagatgcagc	aacgacgtca	cgggccatgt	cgacgtcaca	catattaatg	1800
55	tcacacagac	cgggcgatgg	catcacacag	acgggtgatg	tgtcacacac	agacacagtg	1860
	acaacacaca	ccatgacaac	gacacctata	gatattggc	caacatcaca	tgcacgcatg	1920
	ccctttcaca	cacactttct	acccaattct	cacctagtgt	cacgttcccc	cgaccctggc	1980
	acacgggcca	aggtacccac	aggatcccat	cccctccgc	acagccctgg	gccccagcac	2040</

<212> DNA
<213> Human

<400> 7

5 gccaaaaaga tggcttcaaa agtaagaatg aaacatttga tccattcagc tttaggctat 60
gccactggat tcatgtctag aaaagatagg ataatttctg taaagaaatg aagaccttgc 120
tattctaaaa tcagatcctt acagatccag atttcaggaa acaaatacat aggggactaa 180
10 ctttccttgt tcagattagt ttttctcctt tgcaccagc tatataatat gaggaagtat 240
tgacttttta aaagtgtttt agttttccat ttctttgata tgaaaagtaa tttttcgga 300
gaaccctgag ctattaataa tctatgtggc tagtgcgtat atattggtct gaatttggtc 360
tccttttgtg gtgtccagtg ggtaacatc

<210> 8
<211> 157
<212> DNA
<213> Human

<400> 8

20 tgcttttaaac agctgtgtca aaaactgaca tcagagagta aattgaattt ggttttgtag 60
gaagcaggaa gcaagccac tcaaacgtga aatttggcat gagggatcca gtaactttct 120
cctcaatctg tgaactatat gtgagtttga tattttg

<210> 9
<211> 561
<212> DNA
<213> Human

<400> 9

30 aatagtcaaa acataaaca aagctaatta actggcactg ttgtcacctg agactaagtg 60
gatgttgttg gctgacatac aggtcagcc agcagagaaa gaattctgaa ttccccttgc 120
35 tgaactgaac tattctgtta catatggttg acaaatctgt gtgttatttc ttttctacct 180
accatattta aatttatgag tatcaaccga ggacatagtc aaaccttgc tgatgaacat 240
tcctgatttt ttgcctgatt aatctctgtt gagctctact tgtggtcatt caagatttta 300
tgatgttgaa aggaaaagt aatatgacct ttaaaaattg tattttgggt gatgatagtc 360
tcaccactat aaaactgtca attattgcct aatgtttaaag atatccatca ttgtgattaa 420
40 ttaaacctat aatgagtatt cttaatggag aattcttaat ggatggatta tcccctgata 480
ttttctttta aatttctctg cacacacagg acttctcatt ttccaataaa tgggtgtact 540
ctgcccacat ttctaggaaa a

<210> 10
<211> 1508
<212> DNA
<213> Human

<400> 10

50 cacaaacacg agagactcca cggctctgcct gagcaccgcc agcctcctag gctccagcac 60
tcgcaggtcc attcttctgc acgagcctct ctgtccagat ccataagcac ggtcagctca 120
gggtcgcgga gcagtagcag gacaagtaac agcagcagct cctctgaaca gagactgcta 180
ggatcatcct tctcctccgg gcctgttgcg gatggcataa tccgggtgca acccaaatct 240
55 gagctcaagc caggtgagct taagccactg agcaaggaag atttgggcct gcacgcctac 300
aggtgtgagg actgtggcaa gtgcaaattg aaggagtgc cctacceaa gctcttgcca 360
tcagactgga tctgcgacaa gcagtgcctt tgctcggccc agaactgat tgactatggg 420
acttgtgtat gctgtgtgaa aggtctcttc tatcactggt ctaatgatga tgaggacaac 480
tgtgtctgaca acccatgttc ttgcagccag tctcactggt gtacacgat gtcagccatg 540
60 ggtgtcatgt cctctttttt gccttgttta tgggtgttacc ttccagccaa gggttgccct 600
aaattgtgcc aggggtgtta tgaccgggtt aacaggcctg gttgccgctg taaaaactca 660
aacacagttt gctgcaaagt tcccactgtc ccccttagga actttgaaaa accaacaatag 720
catcattaat caggaatatt acagtaatga ggattttttt tttctttttt taatacacat 780
atgcaaccaa ctaaacagtt ataactcttg cactgttaat agaaagtgtg gatagtcttt 840
ctgttttgcg gtgaaatgct ttttgtccat gtgcccgttt aactgatatg cttgttagaa 900
65 ctcagctaag ggagctcaaa gtatgagata cagaacttgg tgacctatgt attgcataag 960
ctaaagcaac acagacactc ctaggcaaaag tttttgtttg tgaatagtac ttgcaaaaact 1020

	tgtaaattag	cagatgactt	ttttccattg	ttttctccag	agagaatgtg	ctatatTTTT	1080
	gtatatacaa	taatatTTTgc	aactgtgaaa	aacaagtggg	gccatactac	atggcacaga	1140
	cacaaaatat	tatactaata	tgttgtagat	tcggaagaat	gtgaatcaat	cagtatgttt	1200
5	ttagattgta	ttttgcctta	cagaaagcct	ttattgtaag	actctgattt	ccctttggac	1260
	ttcatgtata	ttgtacagtt	acagtaaaat	tcaaccttta	ttttctaat	ttttcaacat	1320
	attgttttagt	gtaaagaata	tttatTTtgaa	gtttttattat	tttataaaaa	agaatattta	1380
	ttttaagagg	catcttacia	atTTtgcccc	ttttatgagg	atgtgatagt	tgctgcaaat	1440
	gaggggttac	agatgcatat	gtccaatata	aaatagaaaa	tatattaacg	tttgaaatta	1500
10	aaaaaaa						
	<210>	11					
	<211>	389					
	<212>	DNA					
	<213>	Human					
15	<400>	11					
	gggcaggtga	tcagggcaca	catttcccgt	ccattgagac	agtagcattc	ccggcaccca	60
20	tcgtgccagc	tctctcatt	tttatgatga	tgaccatcca	cggtgagaca	agtgcccgac	120
	aggatgggtg	gcccagctga	agcacaggcc	gctctgcact	tgagataaag	acagccgtga	180
	ctgtcctgct	ggaaacccaa	ggggcagatc	ttactgcatg	agagctctgg	acatttctta	240
	cagcgacaga	tgacacagcc	gtgcttattc	ttcagcaatc	caagtggaca	atacttgta	300
	cagattatgg	gtctgcactt	cttgggcctt	gggcggcact	cacagatctc	acagttttg	360
25	acctcggccg	cgaccacgct	gggtaccga				
	<210>	12					
	<211>	981					
	<212>	DNA					
	<213>	Human					
30	<400>	12					
	tttttttttt	ttggattgca	aaaattttatt	aaaattggag	acactgtttt	aatcttcttg	60
35	tgccatgaga	ctccatcagg	cagtctacia	agaccactgg	gaggctgagg	atcacttgag	120
	cccagaagtt	tgaggctgta	gtaagcttca	aaggccactg	cactctagct	tgggtgaggc	180
	aagacccttt	caagcagtaa	gctgcatgct	tgcttggtgt	ggtcattaaa	aaccctagtt	240
	taggataaca	acatattaat	cagggcacaa	tacaaatgtg	tgatgcttgt	tagtagagta	300
	acctcagaat	caaaatggaa	cggtttttaca	gtgatatcat	tatatTTcat	ttggcagaat	360
	cattacatca	ttggttacac	tgaaaatcat	cacatgtacc	aaaagctgac	tcacctagtt	420
40	taggataaca	ggtctgcctg	tttgaagatg	aaaaataata	cccattttaa	atttgcctta	480
	ctcaattttcc	ttctcagtc	catttttaact	tttaaacagc	taatcactcc	catctacaga	540
	tttaaggtgta	tatgccacca	aaaccttttg	ccaccttaaa	aatttccttc	aaagtttaaa	600
	ctaattgcctg	catttcttca	atcatgaatt	ctgagtcctt	tgcttcttta	aaacttgctc	660
	cacacagtgt	agtcaagccg	actctccata	cccaagcaag	tcattccatgg	ataaaaaacg	720
45	taccaggagc	agaaccatta	agctggtcca	ggcaagttgg	actccaccat	ttcaacttcc	780
	agctttctgt	ctaattgcctg	tgtgccaatg	gcttgagtta	ggcttgctct	ttaggacttc	840
	agtagctatt	ctcatccttc	cttggggaca	caactgtcca	taaggtgcta	tccagagcca	900
	cactgcatct	gcaccagca	ccatacctca	caggagtcga	ctcccacgag	ccgctgttat	960
50	ataagagttc	ttttgatgac	g				
	<210>	13					
	<211>	401					
	<212>	DNA					
	<213>	Human					
55	<400>	13					
	ataactacag	cttcagcaga	caactaaaga	gactgcatta	aggtgatttc	tctggctata	60
60	aagagagccc	ggccgcagag	catgtgactg	ctgggacctc	tgggataggc	aacactgccc	120
	tctctccccc	agagcgaccc	cccgggcagg	tcggggccca	aggaatgacc	cagcaactgc	180
	tccttaccac	gcacactctc	tttactgcc	cctgcaatta	tgctgtgaag	atgactgggt	240
	gtgggtcatca	cgattcagag	aatcaagat	ctatgacat	tttaggcaaa	gagagaaact	300
	tggagaattg	ctgaggacta	ctgaaccttg	ttttgctttt	ttaaaaata	ctaaatcttc	360
65	acttcagcat	atttagttgt	cattaaaatt	aagctgatat	t		
	<210>	14					

<211> 1002
 <212> DNA
 <213> Human

5 <400> 14

```

gacaatataa aaagtggaaa caagcataaa ttgcagacat aaaataatct tctggtagaa 60
acagttgtgg agaacagggt gagtagagca acaacaacaa aagcttatgc agtcaccttc 120
tttgaaaatg ttaaatataca gtctatttct ctttgtccag ctgggttttag ctagaggtag 180
ccaattactt ctcttaagggt ccatggcatt cgccaggatt ctataaaagc caagttaact 240
gaagtaaata tctggggccc atcgaccccc cactaagtac tttgtcacca tgttgtatct 300
taaaagtcac ttttcactgt ttgactcaga atttgggact tcagagtcaa acttcatttg 360
ttactccaaa cccagtttaa ttccccactt ttttaagtag gcttagcttt gagtgatttt 420
tggctataac cgaaatgtaa atccaccttc aaacaacaaa gtttgacaag actgaaatgt 480
tactgaaaac aatggtgcca tatgctccaa agacatttcc ccaagataac tgccaaagag 540
tttttgagga ggacaatgat catttattat gtaggagcct tgatatctct gcaaaataga 600
attaatacag ctcaaatgga gtagtaacca agcttttctg ccagggaagt aacaaacatc 660
actacgaaca tgagagtaca agaggaaact ttcataatgc attttttcat tcatacatct 720
attcaataaa cattagccaa gctaattgtc caagccactg tgccaggat taacaatata 780
acaacaataa aagacacagt ccttctcttc aaggtgttca gtctagtagg gaagatgatt 840
attcattaaa atttttggtg catcagaatc atgaggagct tgtcaaaaat gtaaattcct 900
gcctatgttc tcagatattc tgggttaggtc aggagtggga acccaaatc aattctttta 960
acaaacacta aaggtgatcc taacacaggc ggtgtgagga cc

```

25 <210> 15
 <211> 280
 <212> DNA
 <213> Human

30 <400> 15

```

cgagggtgggc caccctgtgc tggctctgaga tttttaaatg aggattacat tctcctatct 60
ataatattcc tattctaatac tattgtattc ttacaattaa atgtatcaaa taattcttaa 120
aaacattatt agaaacaaac tgcctaatac cttataagac taaaaaaatc accaagatga 180
aactgtatta tgactctcaa tatttaaaca tttaaaaaaa tgttagtggt tgtaagcac 240
caatcttaac tatttcacct gcccgggcgg ccgctcgagg

```

40 <210> 16
 <211> 2041
 <212> DNA
 <213> Human

<400> 16

```

ccccccgcag aactcccccc tggaatagga tttttaaaac ccttgacaat tagaaatcct 60
atagagggtta gcatttttta ggtaaaaata tgggtgcccc tacagggatc atgcaacttc 120
cttaaaacca attcagcaca tatgtataaa gaaccctttt taaaaacatt tgtacttgaa 180
atacagacac agtgatgctg aagacactaa acaaaaactg aaaagtacta taccttgata 240
aattttgtta ttgccttctt tagagacttt ataactctta gttgattttc aaggacttga 300
atttaataat ggggtaatta cacaagacgt aaaggatttt ttaaaaacaa gtattttttt 360
ttacctctag catcaattct ttataaaga atgctaaata aattacattt tttgttcagt 420
aaaactgaag atagaccatt taaatgcttc taocaaatct aacgcagctt aattagggac 480
caggtagata ttttcttctg aacatttttg gtcaagcatg tctaaccata aaagcaaatg 540
gaatttttaag aggtagattt tttttccatg atgcattttg ttaataaatg tgtcaagaaa 600
ataaaaacaa gcactgagtg tgttctcttg aagtataagg gtctaataaa aaataaaaga 660
tagatatttg ttatagtctg acatttttaac agtcatagta ttagacgttt cgtgaccagt 720
gcatttttga ctctctcagg atcaaaaatac gagtctgcca actgtattaa atcctcctcc 780
acccctccca ccagttggtc cacagcttcc tgggtgggtcg ttgtcatcaa atccattggg 840
ccgaaatgaa catgaagcag atgcagcttg gagggcccg gctcgagcat tcaactcttg 900
ttcctgtaaa tatagtttat tgtcttttgt tatagcatcc ataagttctt tctgtagagg 960
tgggtctcca tttatccaga gtccactggg tgggttatta ccacttaaac cattagtact 1020
atgctgtttt ttatacaaaa gcacataaagc tgtgtccttt ggaaacctgc tcgtaatttt 1080
ctggactgac tgaaatgaag taaatgtcac tctactgtca ttaataaaaa acccattctt 1140
ttgacatttc cttattttcc aaatcctgtt caaaactgac actgggacta tctctcccta 1200
gtaaatgact ctgggaggat gctaagtcca gagcctcaga ctgggtgtac atctgatatg 1260
aagagtctgt acttgtgata tttctggcat aagaatagta atgcccactt tcagaggata 1320

```

	taccagagtg	aaccacaacg	gaacttaata	gatagggcac	caattttgtg	caggaagctt	1380
	catcagtcct	tgaaggcttt	aatttttttag	caaggttctc	actaagatca	gtgaagtcaa	1440
	catctacaga	ccaactttct	gacaatgaag	agaaagaagt	aattcttcta	actggcaact	1500
5	ccaaaaccag	tggccagtga	tacattgtct	aaaattttcc	ttctcacatg	atacttctga	1560
	tcatatgaaa	atctcaggag	agtaagaata	aggatttcag	gttcctccgt	gatttgcata	1620
	gttttctcag	cattttgcag	agaggcacag	ttttcacaat	aattattggt	atcaccagta	1680
	agaatctctg	gagcccaaaa	aataatttag	taagtcagtt	actgaagggt	tggtttcacc	1740
	tcccggtttc	tgaggtagat	ctttattaac	agaatcttg	ttagattcgt	tagggacaga	1800
10	agtgttttca	gaacagtaaa	actcattagg	aggactgcct	atggtttttt	cattcacaaag	1860
	tgagtcacag	atgaaggcag	ctgttggttg	attataaact	actggctctt	ctgaaggacc	1920
	gggtacagac	gcttgcatga	gaccaccatc	ttgtatactg	ggtgatgatg	ctggatcttg	1980
	gacagacatg	ttttccaaag	aagaggaagc	acaaaacgca	agcgaaagat	ctgtaaaggc	2040
	t						
15	<210>	17					
	<211>	235					
	<212>	DNA					
	<213>	Human					
20	<400>	17					
	cgccccgggc	aggtgtcagg	ggttccaaac	cagcctgggg	aaacacagcg	tagacccttc	60
	acctctacaa	ataaaaaatt	aaaaaattag	ccagggtgtg	cagcgaacaa	ctgtagtctc	120
25	agatactcag	gagactgagc	tggaaaggat	cacttgagcc	caagaagttc	aaggttacag	180
	tgggccacga	tcatgtcatt	acactccagc	ttgggtgaca	aatgagact	gtcta	
	<210>	18					
	<211>	2732					
	<212>	DNA					
30	<213>	Human					
	<400>	18					
35	gtgtggagtt	tcagctgcta	ttgactataa	gagctatgga	acagaaaaag	cttgctggct	60
	tcatgttgat	aactacttta	tatggagctt	cattggacct	gttaccttca	ttattctgct	120
	aaatattatc	ttcttgggtg	tcacattgtg	caaaatgggt	aagcattcaa	acactttgaa	180
	accagattct	agcaggttgg	aaaacattaa	gtcttgggtg	cttggcgctt	tcgctcttct	240
	gtgtcttctt	ggcctcacct	ggtccttttg	gttgcttttt	attaatgagg	agactattgt	300
40	gatggcatat	ctcttcacta	tattttaatgc	tttccagga	gtgttcattt	tcatctttca	360
	ctgtgctctc	caaaagaaag	tacgaaaaga	atatggcaag	tgcttcagac	actcatactg	420
	ctgtggaggc	ctcccaactg	agagtcccca	cagttcagtg	aaggcatcaa	ccaccagaac	480
	cagtgtctgc	tattcctctg	gcacacagag	tcgtataaga	agaatgtgga	atgatactgt	540
	gagaaaacaa	tcagaatctt	cttttatctc	aggtgacatc	aatagcactt	caacacttaa	600
	tcaaggtggc	ataaatctta	atatattatt	acaggactga	catcacatgg	tctgagagcc	660
45	catcttcaag	atttatatca	tttagaggac	attcactgaa	caatgccagg	gatacaagtg	720
	ccatggatac	tctaccgcta	aatggtaatt	ttaacaacag	ctactcgctg	cacaaggggtg	780
	actataatga	cagcgtgcaa	gttgtggact	gtggactaag	tctgaatgat	actgcttttg	840
	agaaaatgat	catttcagaa	ttagtgcaca	acaacttacg	gggcagcagc	aagactcaca	900
50	acctcgagct	cacgctacca	gtcaaacctg	tgattggagg	tagcagcagt	gaagatgatg	960
	ctattgtggc	agatgcttca	tctttaatgc	acagcgacaa	cccagggctg	gagctccatc	1020
	acaaagaact	cgaggcacca	cttattcctc	agcggactca	ctcccttctg	taccaacccc	1080
	agaagaaagt	gaagtccgag	ggaactgaca	gctatgtctc	ccaactgaca	gcagaggctg	1140
	aagatcacct	acagtccccc	aacagagact	ctctttatag	aagcatgccc	aatcttagag	1200
55	actctcccta	tccggagagc	agccttgaca	tggagaaga	cctctctccc	tccaggagga	1260
	gtgagaatga	ggacattttac	tataaaagca	tgccaaatct	tggagctggc	catcagcttc	1320
	agatgtgcta	ccagatcagc	aggggcaata	gtgatgggtt	tataatcccc	attaacaaag	1380
	aagggtgtat	tccagaagga	gatgttagag	aaggacaaat	gcagctgggt	acaagtcttt	1440
	aatcatacag	ctaaggaatt	ccaagggcc	catgcgagta	ttaataaata	aagacaccat	1500
	tggctcgacg	agctccctc	aaactctgct	tgaagagatg	actcttgacc	tgtggttctc	1560
60	tgggtgtaaaa	aagatgactg	aaccttgtag	ttctgtgaat	ttttataaaa	catacaaaaa	1620
	ctttgtatat	acacagagta	tactaaagtg	aattattttg	tacaaagaaa	agagatgcc	1680
	gccagggtatt	ttaagattct	gctgctgttt	agagaaattg	tgaacaagc	aaaacaaaac	1740
	tttccagcca	ttttactgca	gcagtctgtg	aactaaat	gtaaatatgg	ctgcaccatt	1800
	ttttagggc	tgcattgtat	tatatacaag	acgttaggct	taaaatcctg	tgggacaaat	1860
65	ttactgtacc	ttactattcc	tgacaagact	tggaaaagca	ggagagatat	tctgcactag	1920
	tttgcagttc	actgcaaate	ttttacatta	aggcaaagat	tgaaaacatg	cttaaccact	1980

	agcaatcaag	ccacaggcct	tatttcatat	gtttcctcaa	ctgtacaatg	aactattctc	2040
	atgaaaaatg	gctaaagaaa	ttatatattt	ttctattgct	agggtaaaat	aaatacattt	2100
	gtgtccaact	gaaatataat	tgtcattaaa	ataattttta	agagtgaaga	aaatattgtg	2160
5	aaaagctctt	ggttgacacat	gttatgaaat	gttttttctt	acactttgtc	atggtaagtt	2220
	ctactcattt	tcacttcttt	tccactgtat	acagtgttct	gctttgacaa	agttagtctt	2280
	tattactttac	attttaaattt	cttattgcca	aaagaacgtg	ttttatgggg	agaaacaaac	2340
	tctttgaagc	cagttatgtc	atgcottgca	caaaagtgat	gaaatctaga	aaagattgtg	2400
	tgtcacccct	gtttattctt	gaacagaggg	caaagagggc	actgggcact	tctcacaaac	2460
10	tttctagtga	acaaaagggtg	cctattcttt	tttaaaaaaa	taaaataaaa	cataaatatt	2520
	actcttccat	attccttctg	cctatatatta	gtaatttaatt	tatttttatga	taaagttcta	2580
	atgaaatgta	aattgtttca	gcaaaattct	gctttttttt	catccctttg	tgtaaacctg	2640
	ttataatga	gcccactcact	aatatccagt	gtaaagttta	acacggtttg	acagtaataa	2700
	aatgtgaatt	ttttcaagtt	aaaaaaaaaa	aa			
15	<210> 19						
	<211> 276						
	<212> DNA						
	<213> Human						
20	<400> 19						
	ctccctaaat	gatttttaaaa	taaattggat	aaacatatga	tataaagtgg	gtacttttaga	60
	aaccgccttt	gcataattttt	tatgtacaaa	tctttgtata	caattccgat	gttccttata	120
25	tattccctat	atagcaaacc	aaaaccagga	cctcccaact	gcatgcctca	agtccctgtg	180
	gagcactctg	gcaactggat	ggccctactt	gctttctgac	aaaatagctg	gaaaggagga	240
	gggaccaatt	aaatacctcg	gccgcgacca	cgctgg			
	<210> 20						
	<211> 2361						
30	<212> DNA						
	<213> Human						
	<400> 20						
35	attgtaccag	ccttgatgaa	cgtgggccc	gcttcgcttt	tgaggggccat	aagctcattg	60
	cccactgggt	tagaggctac	cttatcattg	tctcccgtga	ccggaaggtt	tctcccaagt	120
	cagagttttac	cagcagggat	tcacagagct	ccgacaagca	gattctaaac	atctatgacc	180
	tgtgcaacaa	gttcatagcc	tatagcaccc	tctttgagga	tgtagtggat	gtgcttgctg	240
40	agtggggctc	cctgtacgtg	ctgacgcggg	atgggcgggt	ccacgcactg	caggagaagg	300
	acacacagac	caaactggag	atgctgttta	agaagaacct	atttgagatg	gcgattaacc	360
	ttgccaaagag	ccagcatctg	gacagtgtatg	ggctggccca	gattttcatg	cagtatggag	420
	accatctcta	cagcaagggc	aaccacgatg	gggctgtcca	gcaatatatc	cgaaccattg	480
	gaaagtgtga	gccatcctac	gtgatccgca	agtttctgga	tgcccagcgc	attcacaacc	540
45	tgactgccta	cctgcagacc	ctgcaccgac	aatccctggc	caatgccgac	cataccaccc	600
	tgctcctcaa	ctgctatacc	aagctcaagg	acagctcgaa	gctggaggag	ttcatcaaga	660
	aaaagagtga	gagtgaagtc	cactttgatg	tggagacagc	catcaaggtc	ctccggcagg	720
	ctggctacta	ctcccattgcc	ctgtatctgg	cggagaacca	tgacatcat	gagtgggtacc	780
	tgaagatcca	gctagaagac	attaagaatt	atcaggaagc	ccttcgatac	atcggaagc	840
50	tgcccttttga	gcaggcagag	agcaacatga	agcgtacgg	caagatcctc	atgcaccaca	900
	taccagagca	gacaactcag	ttgctgaagg	gactttgtac	tgattatcgg	cccagcctcg	960
	aaggccgcag	cgataggag	gccccaggct	gcagggccaa	ctctgaggag	ttcatcccca	1020
	tctttgccaa	taaccgcga	gagctgaaag	ccttcctaga	gcacatgagt	gaagtgcagc	1080
	cagactcacc	ccaggggatc	tacgacacac	tccttgagct	gcgactgcag	aactgggccc	1140
55	acgagaaggga	tccacaggtc	aaagagaagc	ttcacgcaga	ggccatttcc	ctgctgaaga	1200
	gtggctcgctt	ctgcgacgtc	tttgacaagg	ccctggctct	gtgccagatg	cacgacttcc	1260
	aggatgggtg	cctttacctt	tatgagcagg	ggaagctgtt	ccagcagatc	atgcactacc	1320
	acatgcagca	cgagcagtac	cggcaggctc	tcagcgtgtg	tgagcgccat	ggggagcagg	1380
	acccctcctt	gtgggagcag	gccctcagct	acttcgctcg	caaggaggag	gactgcaagg	1440
60	agtatgtggc	agctgtcctc	aagcatatcg	agaacaagaa	cctcatgcc	cctcttctag	1500
	tggtgcagac	cttggcccac	aactccacag	ccacactctc	cgtcatcagg	gactacctg	1560
	tccaaaaact	acagaaacag	agccagcaga	ttgcacagga	tgagctgcgg	gtgcggcggt	1620
	accgagagga	gaccacccgt	atccgcccag	agatccaaga	gctcaaggcc	agtcctaaga	1680
	ttttccaaaa	gaccaagtgc	agcatctgta	acagtgcctt	ggagttgccc	tcagtccaat	1740
65	tctctgtgtg	ccactctgtg	caccaacact	gctttgagag	ttactcggaa	agtgtgctg	1800
	actgcccac	ctgcctcctt	gaaaaccgga	aggtcatgga	tatgatccgg	gccagggaac	1860
	agaaacgaga	tctccatgat	caattccagc	atcagctcaa	gtgctccaat	gacagctttt	1920

5	ctgtgattgc	tgactacttt	ggcagaggtg	ttttcaacaa	attgactctg	ctgaccgacc	1980
	ctcccacagc	cagactgacc	tccagcctgg	aggctgggct	gcaacgcgac	ctactcatgc	2040
	actccaggag	gggcacttaa	gcagcctgga	ggaagatgtg	ggcaacagtg	gaggaccaag	2100
	agaacagaca	caatgggacc	tgggcggggc	ttacacagaa	ggctggctga	catgcccagg	2160
	gctccactct	catctaattg	cacagccctc	acaagactaa	agcggaaactt	tttcttttcc	2220
	ctggccttcc	ttaattttta	gtcaagcttg	gcaatccctt	cctcttttaac	taggcagggtg	2280
	ttagaatcat	ttccagatta	atggggggga	aggggaacct	caggcaaacc	tcctgaagtt	2340
	ttggaaaaaa	aagctggttt	c				
10	<210> 21						
	<211> 179						
	<212> DNA						
	<213> Human						
15	<400> 21						
	agggtgttaga	tgctcttgaa	aaagaaactg	catctaagct	gtcagaaatg	gattctttta	60
	acaatcaact	aaaggaactg	agagaaacct	acaacacaca	gcagttagcc	cttgaacagc	120
	tttataagat	caacgtgaca	agttgaagga	aattgaaagg	aaaaaattag	aactaatgc	
20	<210> 22						
	<211> 905						
	<212> DNA						
	<213> Human						
25	<400> 22						
	tttttttttt	ttctttaacc	gtgtggtctt	tatttcagtg	ccagtgttac	agatacaaca	60
	caaagtgttc	agttagaagg	aattcaaacg	gaatgccaa	gtccaagcca	ggctcaagaa	120
	ataaaaagg	aggtttgagg	taatagataa	gatgactcca	atactcactc	ttcctaagg	180
	caaagggtact	tttgatacag	agtctgatct	ttgaaactgg	tgaactcctc	ttccaccat	240
	taccatagtt	caaacaggca	agttatgggc	ttaggagcac	tttaaaattt	gtgggtggaa	300
	tagggtcatt	aataactatg	aataatatct	ttagaagggtg	accatttttg	actttaaagg	360
	gaatcaattt	tgaaaatcat	ggagactatt	catgactaca	gctaaagaat	ggcgagaaag	420
	gggagctgga	agagccttgg	aagtttctat	tacaaataga	gcaccatatc	cttcatgcc	480
	aatctcaaca	aaagctcttt	ttaactccat	ctgtccagtg	tttacaata	aactcgcaag	540
	gtctgaccag	ttcttggtta	caaacataca	tgtgtgtgtc	tgtgtgtata	cagcaatgca	600
	cagaaaaggc	taccaggagc	ctaattgcctc	tttcaaacc	tgggggaacc	agtagaaaa	660
	ggcagggctc	cctaattgtc	attattacat	ttccattccg	aatgccagat	gttaaaagt	720
	cctgaagatg	gtaaccagc	tagtgaggaa	taaatacccc	accttgccca	gtccacagag	780
	aaacaacagt	agaaagaagg	ggcaactctt	tgctgcagag	acaaagtgag	tgttttttcg	840
	ccatggattg	cagtcctctc	ctccagacca	gctgcttatt	tcctcagggg	cccagggaa	900
	gttga						
45	<210> 23						
	<211> 2134						
	<212> DNA						
	<213> Human						
50	<400> 23						
	ggctctctct	ttcttttttt	tttttccaaa	agtgttcttt	tatttctagt	aacatatatt	60
	gtataaatac	tctatttttat	atgcacttcc	acaaaagcga	tataatttaa	aagttttttt	120
	cattagaaat	aaatgtataa	aaataaatat	gttattatag	gcattttatta	ctaactatag	180
	tccttcttgg	aaggaacacc	caaaccaata	cttataaagt	acatgtaatt	tatagtaaca	240
	tatttttacta	tatacatatg	gaaaaaatca	tattctcaca	gaagagctga	acagacattc	300
	accaggatac	gactgttgga	ccagctgctg	gagatggacc	tgctaccctc	cagcagcctc	360
	cccaccacaa	gacaagtgat	ctcaatgtcc	ccaaacctgt	gggacctgt	tctacacacc	420
	tcatttttgt	tccggcggtt	catcctcctt	gtgtgattgt	actgattttc	atgagacaca	480
	agttacttct	ttacatccat	attcccaaag	caggggttaca	tggtaggaaa	gaaagggaag	540
	tggaggtact	aagctcattg	tgctctcctt	agctttttacc	agcatctaat	gcttctactgc	600
	ttttttttcca	ttgtagactt	taatgcactt	gaataaatac	atggagttgt	tttttctca	660
	aaatgaatta	cacaaataaa	gactgagatg	gtccaaaaaa	ggaaagagga	agccatttgc	720
	gttattttcac	gttgctgagc	ctttctctca	tggtgaacaa	tctgaagttt	taattctcgg	780
	tagaaataat	gtataaacat	tctctgaaac	catagcagcc	ataaacagtg	ctgggtcaaa	840
	atcctatttg	tactcctttc	tccccccatt	gttagtgagg	taaagtaaaa	caggtcttag	900

5 taaaatctca cttttctcct acttttccatt toccaacccc catgatacta agtatttggat 960
 aagtaccagg aaacaggggt tgtaatagtt ctaacttttt ttgacaattg ctttgttttt 1020
 tctaaacttg taatagatgt aacaaaagaa ataataataa taatgcccg ggctttatta 1080
 tgctatatca ctgctcagag gttaataatc ctcactaact atcctatcaa atttgcaact 1140
 ggcagtttac tctgatgatt caactccctt tctatctacc ccataatcc caccttactg 1200
 atacacctca ctggttactg gcaagatacg ctggatccct ccagccttct tgctttccct 1260
 gcaccagccc ttctcacttt tgccttgccc tcaaagctaa caccacttaa accacttaac 1320
 tgcattctgc cattgtgcaa aagtctatga aatgtttagg tttcttttaa ggatcacagc 1380
 10 tctcatgaga taacaccctt ccatcatggg acagacactt caagcttctt tttttgtaac 1440
 ccttcccaca ggtcttagaa catgatgacc actccccag ctgccactgg gggcagggat 1500
 ggtctgcaca aggtctgggt ctggctgggt tcaacttctt tgcacactcg gaagcaggct 1560
 gtccattaat gtctcggcat tctaccagtc ttctctgcca acccaattca catgacttag 1620
 aacattcgcc ccactcttca atgacccatg ctgaaaaagt ggggatagca ttgaaagatt 1680
 ccttcttctt ctttacgaag taggtgtatt taattttagg tcgaagggca ttgccacag 1740
 15 taagaacctg gatggtcaag ggctctttga gagggctaaa gctgcgaatt ctttccaatg 1800
 ccgcagagga gccgctgtac ctcaagacaa cacctttgta cataatgtct tgctctaagg 1860
 tggacaaagt gtagtacca ttaagaatat atgtgccatc agcagctttg atggcaagaa 1920
 agctgccatt gttcctggat cccctctggg tccgctgttt cacttcgatg ttggtggctc 1980
 cagttggaat tgtgatgata tcatgatatc caggttttgc actagtaact gatcctgata 2040
 20 tttttttaca agtagatcca tttccccgc aaacaccaca tttatcaaac ttctttttgg 2100
 agtctatgat gcgatcacia ccagctttta caca

<210> 24

<211> 1626

25 <212> DNA

<213> Human

<400> 24

30 ggacaatttc tagaatctat agtagtatca ggatatattt tgctttaaaa tatatttttg 60
 ttattttgaa tacagacatt ggctccaaat tttcatcttt gcacaatagt atgacttttc 120
 actagaactt ctcaacattt gggaaactttg caaatatgag catcatatgt gttaaaggctg 180
 tatcatttaa tgctatgaga tacattgttt tctccctatg ccaaacaggt gaacaaacgt 240
 35 agttgttttt tactgatact aaatgtttggc tacctgtgat tttatagtat gcacatgtca 300
 gaaaaaggca agacaaatgg cctctgttac tgaatacttc ggcaaaactta ttgggtcttc 360
 attttctgac agacaggatt tgactcaata tttgtagagc ttgcgtagaa tggattacat 420
 ggtagtgatg cactggtaga aatggttttt agttattgac tcagaattca tctcaggatg 480
 aatcttttat gtctttttat tghtaagcata tctgaattta ctttataaag atggttttag 540
 aaagctttgt ctaaaaattt ggccctaggaa tggtaacttc attttcagtt gccaaaggggt 600
 40 agaaaaataa tatgtgtgtt gttatgttta tgttaacata ttattaggta ctatctatga 660
 atgtatttaa atatttttca tattctgtga caagcattta taatttgcaa caagtggagt 720
 ccatttagcc cagtgggaaa gtcttggaaac tcagggttacc cttgaaggat atgctggcag 780
 ccactctctt gatctgtgct taaactgtaa tttatagacc agctaaatcc ctaacttggg 840
 45 tctggaatgc attagttatg ccttgtaacca ttcccagaat ttcaggggca tctggtgggtt 900
 ggtctagtga ttgaaaacac aagaacagag agatccagct gaaaaagagt gatcctcaat 960
 atcctaacta actggtcctc aactcaagca gagtttcttc actctggcac tgtgatcatg 1020
 aaacttagta gaggggattg tgtgtatttt atacaaattt aatacaatgt cttacattga 1080
 taaaattctt aaagagcaaa actgcatttt atttctgcat ccacattcca atcatattag 1140
 50 aactaagata tttatctatg aagatataaa tgggtgcagag agactttcat ctgtggattg 1200
 cgttgtttct tagggttcct agcactgatg cctgcacaag catgtgatat gtgaaataaa 1260
 atggattctt ctatagctaa atgagttccc tctggggaga gttctggtac tgcaatcaca 1320
 atgccagatg gtgtttatgg gctatttgtg taagtaagtg gtaagatgct atgaagtaag 1380
 tgtgtttgtt ttcactctat ggaaactctt gatgcatgtg cttttgtatg gaataaattt 1440
 55 tggtgcaata tgcgtcatt caactttgca tttgaattgaa ttttgggtgt atttatatgt 1500
 attataacct tcacgcttct agttgcttca accattttt aaccattttt gtacataatt 1560
 tacttgaaaa tatttttaaat ggaaatttaa ataaacattt gatagttttac ataataaaaa 1620
 aaaaaa

<210> 25

60 <211> 1420

<212> DNA

<213> Human

<400> 25

65 gttcagcatt gtttctgctt ctgaaatctg tatagtacac tggtttggtaa tcattatgtc 60

5	ttcatttgaaa acacaagctt ttggaacaaa agtgggaaaa tccttgctac tattttataa atgggtttcac ttaatgctta tcagccttgc agggtggaga atccttttga tgtatatagt tttgctctgt accagtacct tgtattttcc gtggccttgt catgagttag tcgacacatt acatcaatct tatagaiaatt atacagcact tctttgtaat agtaataaaa	tccttgctac aagaaaaacg aaacatgaag ctttaagagt gggagacact ggcccataaa tgccatcagc aaattatata catgtatcag aagaggtact tgggaggaga tgagaatttt tttgccctgaa ggggagggtta tccagagatt ttttttttct ggagactgaa ttttttcagt atgcataaat ttttataactg ttgcacaaaa tgggttgtgg gtgtccttta	ttcttttctc agcaaggaag gactccaact ttccacatat agtagtatat tactggttaa catgctgata taaaatgctt tttcaacttga ggaaaacatg gttactcctt acgacacttt gttttagtat gatgtgtgtt ttgaacttta caagtaaaat gagttattgta aacttgaaaa ggcagcctgt attgggttcat tgagtgtagc tgcattttgc acttcaaaaa	cctcaatgaa agtatcttca agaagacaga tagttttcat gtttgtaagt actctgttaa tattagaaat tatttagaaa aatttgagac cagatgagga aaaggcaggc taaaaattgt ttgttttcta tcaggccttg ataattgcgt tgtgaacata gactgtacat ttcaaaagg tttcttgagc agatggctcag attgtttaaa actacctgga aaaaaaaaa	agacacagga gacaagagcg ttatttctcat tattttacatt tttttgagtc ttacttttaa aagtgggcct ggcatcccta acctacatga caattaaatt tatcttttat agcttaagt gtaattgtta ggtggacctc agtgtatgag gtgtgttttt tttcttttat gtgccttctt acatttggtt cactgtctaa ttttgtacac cattgtgtgt gttacagttt	gacaagagcg tttctctgag taaataagatt aagagactgc attatctttt tctatcttgg tctacttact tacagtgggtg tcaactgttt gtgcaacagt gacaatgttt aatgtccagt tgaaaaccaa tgggttttgc ttttttttta aggggcagg aatgtgtttc agggttactgt attttgtttt agactgaaca taaacactgt tcaatctgtc	120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1140 1200 1260 1320 1380
25	<210> 26 <211> 689 <212> DNA <213> Human						
30	<400> 26						
35	aaacaaacaa caaacaatta cttaaaataag ggtaactcag cacttgcttc catttggggc tcgaagcgtg attccaaatg gaggtggctg tgtcaagatg ctgtgatgaa cacacccaga	aaaaaaagtt tagcacatcc tgctaaacat ctagtttaca tgcaccattt cagggtgattc gtcgcggccg accgaaggaa gaggtaacgc tgccattaaa gtaatcaatg gcctgaagtt	agtactgtat ttcctttttac acatatacgg ctgtttccag atcacaccag ttccttgcaa aggtactgaa caaagcttca agcttccattt tcaggcaggt aaacaccgga tgtccttcg	atgtaaatac tctgtctcac aacttgaaag ggagtagttg gacagggtct gggctgtcct aggaccaagg gggctctggg cgtccagtc ctacaaaggc acctccgacc	tagcttttca ctccttttagg ctttgggttag aattactata ctcaacctgg gtacctgccc agctctggct tggtgtctcc tttccagtat atcccgaagca acctcctgaa	atgtgctata tgagtacttc ccttgcccta aaccattagc gggctgctgt ggcgccgcgc gccctcaggga cactattcag ttaaagttgt tcaaacatgt tagtgggaga	60 120 180 240 300 360 420 480 540 600 660
45	<210> 27 <211> 471 <212> DNA <213> Human						
50	<400> 27						
55	tcccagcggc ccctctcgct agccctaacc ccagccacca gggtacaggc tgggctgggt tgggcaattt ggacagaggg	atgaagtttg cattgggtggc caggcccccgc gtgccttaca tgaacgacta cccggcggga ttgtatccaa ggaaataaaga	agattggcca accctgcttt ccaggggccac aagacaatcg cgtgtgagtc ctgtcaatgg ggaaataatg ggaggagaaa	ggcctgttac gcctgtcctg cacgaccact ggcccccctca cccacagcct aggcaggggt tgaatgcgag gctctctata	ctgggcttca ccaggacgag gcaaacaccg gtgacctcgg gcttctccc tccagcacia gaaatgtctt caaagactg	tctccttcgt gcaccctaca cacctgccta ccaccacagc tgggctgctg agtttacttc tagagcacag a	60 120 180 240 300 360 420
60	<210> 28 <211> 929 <212> DNA <213> Human						
65	<400> 28						

	ggtgaactca	gtgcattggg	ccaatggttc	gacacaggct	ctgccagcca	caaccatcct	60
	gctgcttctg	acggtttggc	tgctgggtgg	ctttcccctc	actgtcattg	gaggcatcct	120
5	tggaagaac	aacgccagcc	cctttgatgc	accctgtcgc	accaagaaca	tcgcccggga	180
	gattccaccc	cagccctggt	acaagtctac	tgtcatccac	atgactgttg	gaggcttcct	240
	gcctttcagt	gccatctctg	tgagagctgta	ctacatcttt	gccacagtat	ggggtcggga	300
	gcagtacact	ttgtacggca	tcctcttctt	tgtcttcgcc	atcctgctga	gtgtgggggc	360
	ttgcatctcc	attgcactca	cctacttcca	gttgtctggg	gaggattacc	gctgggtggtg	420
10	gcgatctgtg	ctgagtgttg	gctccaccgg	cctcttcata	ttcctctact	cagttttcta	480
	ttatgcccg	cgctccaaca	tgtctggggc	agtacagaca	gtagagtctt	tcggctactc	540
	cttactcact	ggttatgtct	tcttcctcat	gctgggcacc	atctcctttt	tttcttccct	600
	aaagttcatc	cggatatatc	atgttaacct	caagatggac	tgagtctctg	atggcagaac	660
	tattgctgtt	ctctcccttt	cttcatgccc	tgttgaactc	tcctaccagc	ttctcttctg	720
15	attgactgaa	ttgtgtgatg	gcattgttgc	cttccctttt	tccttttggg	cattccttcc	780
	ccagagaggg	cctggaaatt	ataaatctct	atcacataag	gattatata	ttgaactttt	840
	taagttgcct	ttagttttgg	tcctgatatt	tctttttaca	attaccaaaa	taaaatttat	900
	taagaaaaag	aaaaaaaaaa	aaaaaaaaaa				
20	<210> 29						
	<211> 1775						
	<212> DNA						
	<213> Human						
25	<400> 29						
	gaacgtgatg	ggaacttttg	gaggatgtct	gagaaaaatgt	ccgaagggat	tttggccaac	60
	accagaaaaac	gccaatgtcc	taggaattcc	ctcccaaat	gcttcccaa	aaattactca	120
	ttgacaattc	aaattgcact	tggtggcg	cagcccg	ggccttcagt	ccgtgtgggg	180
30	cgcccgcg	gccttctcct	cgtaggactc	cccaaactcg	ttcactctgc	gtttatccac	240
	aggataaagc	caccgctgg	acaggtagac	cagaaacacc	acgtcgtccc	ggaagcaggc	300
	cagccggtga	gacgtgggca	tggtgatgat	gaaggcaaa	acgtcatcaa	tgaagggtgt	360
	gaaagccttg	taggtgaagg	ccttccagg	catagtgtgc	actgacttca	acttgtagtt	420
	cacaaagagc	tggggcagca	tgaagaggaa	accaaaggca	tagaccccg	tgacgaagct	480
35	gttgattaac	caggagtacc	agctcttata	tttgatatcc	aggagtgaat	agacagcacc	540
	cccgacacag	agagggtaca	gcaggtagat	caagtacttc	atggcctgag	tatcgtactc	600
	ctcggttttc	ctctcagatt	cgctgtaagt	gccaaactga	aattcgggca	tcaggcctct	660
	ccaaaaaata	gtcatcttca	atgccttctt	cactttccac	agctcaatgg	cggctccaac	720
	accgcgcggg	accagcacca	gcaggctcgt	ctgctcgtcc	agcaggaaca	gaaagatgac	780
40	cacgggtgctg	aagcagcgcc	agagcactgc	cttgggtggac	atgccgatca	tgctcttctt	840
	cttcttccag	aaactgatgt	cattttttaa	ggccaggaaa	tcaaagagaa	gatggaacgc	900
	tgcgacaaa	aaggtcagcg	ccagggaagta	taagttggta	tctacaaaaa	ttcctttcac	960
	ctcatcagca	tctttctctg	aaaaccogaa	ctgctgcagg	gagtacacgg	cgtcctgcat	1020
	gtggatccag	aagcgcagcc	gcccagtgta	gaccttgtcg	taggacacgg	tgaggggcag	1080
45	ctcggtggtg	gagcggttta	tgaccatcag	gtccttcacg	cggttgctga	gctggtcgat	1140
	gaacaggatg	ggcaggtaat	gcacggtttt	ccccagctgg	atcatcttca	tgtaccgatg	1200
	cacatcggca	ggcaggggag	acccgtcaaa	gacaaagtgt	tcgcccata	cgttcagcgc	1260
	cagccgcggt	cgccagtggg	acactggctc	atccagggca	ctcgtcggct	tcttctccgc	1320
	ctcgatctgc	tgtgtatcag	actccccgg	gagcagggtg	atttcttctg	gcttggggac	1380
50	catgtagggtg	gtcagaggac	tgaccagggtg	cacctgcttc	ccgtcgtgcc	acggcaggac	1440
	cccagcgtga	tggaggaaga	tgtaggcata	cagcgtccca	ttgtttctcg	ttttctttgg	1500
	tacagaaaca	ttactgtcc	tttcaaattt	ggactccaca	tcaaagtctt	ccacattcaa	1560
	gaccagggtcg	atgttgttct	cagcaccag	gtgggacctc	gtcgtgggtg	acacgctcag	1620
	ctgcagcttg	ggccgcgcg	ccaggtaggg	ctggatgcag	ttggcgtcgc	cggagcacgg	1680
55	gcgggtgtag	acgatgccgt	acatgacca	gcagggtg	accacgtaga	ccacgaacac	1740
	gccaccacc	aagctgggtga	aggagctgcg	gcccc			
60	<210> 30						
	<211> 1546						
	<212> DNA						
	<213> Human						
65	<400> 30						
	aaaataagta	ggaatgggca	gtgggtattc	acattcacta	caccttttcc	atttgcta	60
	aaggccctgc	caggctggga	gggaattgtc	cctgcctgct	tctggagaaa	gaagatattg	120

	acaccatcta	cgggcacccat	ggaactgctt	caagtgaacca	ttcttttttct	tctgcccagt	180
	atttgcagca	gtaacagcac	aggtgtttta	gaggcagcta	ataattcact	tggtgttact	240
	acaacaaaac	catctataac	aacaccaaac	acagaatcat	tacagaaaaa	tggtgtcaca	300
5	ccaacaactg	gaacaactcc	taaaggaaca	atcaccaatg	aattacttaa	aatgtctctg	360
	atgtcaacag	ctactttttt	aacaagtaaa	gatgaaggat	tgaaagccac	aaccactgat	420
	gtcaggaaga	atgactccat	catttcaaac	gtaacagtaa	caagtgttac	acttccaaat	480
	gctgtttcaa	cattacaaaag	ttccaaaccc	aagactgaaa	ctcagagttc	aattaaaaaca	540
	acagaaatac	caggtagtgt	tctacaacca	gatgcatcac	cttctaaaac	tggtacatta	600
10	acctcaatac	cagttacaat	tccagaaaac	acctcacagt	ctcaagtaat	aggcactgag	660
	ggtggaaaaa	atgcaagcac	ttcagcaacc	agccggtctt	attccagtat	tattttgccg	720
	gtggttattg	ctttgattgt	aataacactt	tcagtatttg	ttctggtggg	tttgtaccga	780
	atgtgctgga	aggcagatcc	gggcacacca	gaaaatggaa	atgatcaacc	tcagtctgat	840
	aaagagagcg	tgaagcttct	taccgttaag	acaatttctc	atgagtctgg	tgagcactct	900
15	gcacaaggaa	aaaccaagaa	ctgacagctt	gaggaattct	ctccacacct	aggcaataat	960
	tacgcttaat	cttcagcttc	tatgcaccaa	gcgtggaaaa	ggagaaagtc	ctgcagaatc	1020
	aatcccagct	tccataacctg	ctgctggact	gtaccagacg	tctgtcccag	taaagtgatg	1080
	tccagctgac	atgcaataat	ttgatggaat	caaaaagaac	cccggggctc	tcctgttctc	1140
	tcacatttaa	aaattccatt	actccattta	caggagcggt	cctaggaaaa	ggaatttttag	1200
20	gaggagaatt	tgtgagcagt	gaatctgaca	gccaggagg	tgggctcgct	gataggcatg	1260
	actttcctta	atgtttaaag	ttttccgggc	caagaatttt	tatccatgaa	gactttccta	1320
	cttttctcgg	tgttcttata	ttacctactg	ttagtattta	ttgtttacca	ctatgttaat	1380
	gcagggaaaa	gttgcacgtg	tattattaaa	tattaggtag	aaatcatacc	atgctacttt	1440
	gtacatatata	gtatttttatt	cctgctttcg	tgttactttt	aataaataac	tactgtactc	1500
25	aataactctaa	aaataactata	acatgactgt	gaaaatggca	aaaaaa		
	<210>	31					
	<211>	750					
	<212>	DNA					
	<213>	Human					
30	<400>	31					
	cacttgggca	ccccattttt	ctaaaaaaat	ggaaatctgg	agggcaaaaa	aggtgtgctg	60
35	aagggaagtg	cctctgatgg	cccaaaaacc	ttcttccaaa	ctagtgtagg	aatggaatgg	120
	atagcaaagt	gatccttttt	ggcctccttt	ggagcatgcc	ttccctatct	tatccttggc	180
	ccactaaag	cagaacgtta	cggatatttc	tgtttttgcc	attggatgcc	tatctggcca	240
	aacagccttt	ccctaattgg	aaaatgcagt	cctgtttaaa	acctttgatt	tacgactact	300
	tgtacatgct	tgctcattac	aattttgaca	ttttttacat	agtgaagacc	ccaaacatat	360
40	cagtgaacaa	tgacaagatc	ataaagaaca	gtatcatatt	attattttagt	cgctttttaca	420
	gtggcaagcc	aattttgaaa	tatctcattt	aaaactcaga	cccaattcac	tgagttatac	480
	ttttaatagc	ttcctcagca	cactattttcc	catgcattaa	atatgataaa	ataatctatc	540
	actgcccata	ggtcttgtaa	aaaggaagtc	tgaatacaga	gcccaacaaca	ctaaaattgt	600
	ttttctagct	acaaagtata	gcacatcatc	cacagacacg	atttggactc	cctgacaggt	660
45	ggattggaaa	acggtgttta	aaagagaagag	aacatttttaa	cataaatgtc	attaagaatc	720
	ccaaaggcct	tattttgtcac	caccgtcccg				
	<210>	32					
	<211>	1620					
	<212>	DNA					
50	<213>	Human					
	<400>	32					
	gcaattcccc	cctcccacta	aacgactccc	agtaattatg	tttacaaccc	attggatgca	60
55	gtgcagccat	tcataagaac	cttgggtgcc	cagaaaaatc	tgtccttttt	ggtacaaaac	120
	ctgagggtctt	ttggaagata	atgtagaaaa	ccactaccta	ttgaaggcct	gttttggcta	180
	atctgtgcaa	actctgatga	tacctgcctt	atgtggattc	ttttccacac	tgctttcatt	240
	tttaagtata	aagacttaga	aaactagaat	aatgctttta	caaataatta	aaagtatgtg	300
	atgttctggy	ttttttcctt	cttttttagaa	ccccgcctcc	atttaaaaaa	ttaaaaaaa	360
60	aaaaaaaaact	tttaacattt	aaaaaataaa	aattaacaaa	atttcactta	ttccaggaca	420
	cgctggcatt	tggactcaat	gaaaagggca	cctaaagaaa	ataaggctga	ctgaatgttt	480
	tccataattt	tcacacaata	acagtccttt	tctatccagc	ttgccttcca	tttatctcta	540
	gggttagctt	ttcaggcaac	atccttggtc	attgcccaga	aagtacctga	gctatcagtg	600
	attggaatgg	cacaggaac	cgaatcacat	gggtgccttc	cccttggttt	tcaagtatct	660
65	tgagtttggt	gcacaaaaat	aggctatgcc	ttcagtgctc	tgttctttta	acctaccctt	720
	tgacaatcag	gtgctaataa	ttgtatacta	ttaaaaccag	cacataagta	ttgtaaatgt	780

	gtgttctctcc	taggtttggaa	gaaatgtctt	tcctttctatc	tgggtcctgt	taaagcgggt	840
	gtcagttgtg	tcttttcacc	tcgattttgtg	aattaataga	attgggggga	gaggaaatga	900
	tgatgtcaat	taagtttcag	gttttggcatg	atcatcattc	tcgatgatat	tctcactttg	960
5	tcgcaaactc	gcccttatcg	taagaacaag	tttcagaatt	ttccctccac	tatacgactc	1020
	cagtattatg	tttacaatcc	attggatgag	tgcagcatta	taagaccttg	gtgccagaa	1080
	aaatctgtcc	tttttggtag	caaacctgag	gtcttttggg	agataatgta	gaaaaccact	1140
	acctattgaa	ggcctgtttt	ggctaactctg	tgcacactct	gatgatacct	gcttatgtgg	1200
	attcttttcc	acactgcttt	cattttttaag	tataaagact	tagaaaacta	gaataatgct	1260
10	tttacaata	attaaaagta	tgtgatgttc	tgggtttttt	ccttcttttt	agaacctgt	1320
	atthaaacaa	gccttctttt	taagtcttgt	ttgaaattta	agtctcagat	cttctggata	1380
	ccaaatcaaa	aacccaacgc	gtaaaacagg	gcagtatttg	tgttcctaata	tttaaaaagc	1440
	tttatgtata	ctctataaat	atagatgcat	aaacaacact	tccccttgag	tagcacatca	1500
	acatacagca	ttgtacatta	caatgaaaat	gtgtaactta	agggtattat	atatataaat	1560
15	acatatatac	ctttgttaacc	tttatactgt	aaataaaaaa	gttgcttttag	tcaaaaaaaa	1620
	<210> 33						
	<211> 2968						
	<212> DNA						
	<213> Human						
20	<400> 33						
	gaaaaagtag	aaggaaacac	agttcatata	gaagtaaaag	aaaaccctga	agaggaggag	60
25	gaggaggaag	aagaggaaga	agaagatgaa	gaaagtgaag	aggaggagga	agaggaggga	120
	gaaagtgaag	gcagtgaagg	tgatgaggaa	gatgaaaagg	tgtcagatga	gaaggattca	180
	gggaagacat	tagataaaaa	gccaagtaaa	gaaatgagct	cagattctga	atatgactct	240
	gatgatgatc	ggactaaaaga	agaaagggct	tatgacaaaag	caaaacggag	gattgagaaa	300
	cggcgacttg	aacatagtaa	aaatgtaaac	accgaaaagc	taagagcccc	tattatctgc	360
30	gtacttgggc	atgtggacac	agggaaagaca	aaaattcttag	ataagctccg	tcacacacat	420
	gtacaagatg	gtgaagcagg	tgtatcacaca	caacaaattg	gggccaccaa	tgttcctctt	480
	gaagctatta	atgaacagac	taagatgatt	aaaaattttg	atagagagaa	tgtacggatt	540
	ccaggaaatgc	taattattga	tactcctggg	catgaatctt	tcagtaatct	gagaaataga	600
	ggaagctctc	tttgtgacat	tgccatttta	gttggtgata	ttatgcatgg	tttgagccc	660
35	cagacaattg	agtctatcaa	ccttctcaaa	tctaaaaaat	gtcccttcat	tgttgactc	720
	aataagattg	ataggtttata	tgatttgaaa	aagagtcctg	actctgatgt	ggctgctact	780
	ttaaagaagc	agaaaaagaa	tacaaaagat	gaattttgagg	agcgagcaaa	ggctattatt	840
	gtagaatttg	cacagcaggg	tttgaatgct	gctttgtttt	atgagaataa	agatccccgc	900
	acttttgtgt	cttttggtag	tacctctgca	catactggtg	atggcatggg	aagtctgac	960
40	taccttcttg	tagagttaac	tcagaccatg	ttgagcaaga	gacttgacac	ctgtgaagag	1020
	ctgagagcac	aggtgatgga	ggttaaagct	ctcccgggga	tgggcaccac	tatagatgtc	1080
	atcttgatca	atgggcgttt	gaaggaaagga	gatacaatca	ttgttccttg	agtagaaggg	1140
	cccattgtaa	ctcagattcg	aggcctcctg	ttacctctc	ctatgaagga	attacgagtg	1200
	aagaaccagt	atgaaaagca	taaagaagta	gaagcagctc	agggggtaaa	gattctgga	1260
45	aaagacctgg	agaaaacatt	ggctggttta	ccccctcctg	tggcttataa	agaagatgaa	1320
	atccctgttc	ttaaagatga	attgatccat	gagttaaagc	agacactaaa	tgctatcaaa	1380
	ttagaagaaa	aaggagtcta	tgtccaggca	tctacactgg	gttcttttga	agctctactg	1440
	gaatttctga	aaacatcaga	agtgccttat	gcaggaatta	acattggccc	agtgcataaa	1500
	aaagatgtta	tgaaggcttc	agtgatgttg	gaacatgacc	ctcagtatgc	agtaattttg	1560
50	gccttcgatg	tgagaattga	acgagatgca	caagaaatgg	ctgatagttt	aggagttaga	1620
	atttttagtg	cagaaattat	ttatcattta	tttgatgcct	ttacaaaata	tagacaagac	1680
	tacaagaaac	agaaacaaga	agaattttaag	cacatagcag	tatttccctg	caagataaaa	1740
	atcctccctc	agtacatttt	taatttctga	gatccgatag	tgatgggggt	gacggtggaa	1800
	gcaggtcagg	tgaagcaggg	gacacccatg	tgtgtcccaa	gcaaaaattt	tggtgacatc	1860
55	ggaatagtaa	caagtagtta	aataaaacct	aaacaagtgg	atggttgcaa	aaaagacaaa	1920
	gaagtttgtg	taaaaataga	acctatccct	ggtgagtcac	ccaaaatgtt	tggaagacat	1980
	tttgaagcta	cagatattct	tgtagtaag	atcagccggc	agtccattga	tgactcaaaa	2040
	gactggttca	gagatgaaat	gcagaagagt	gactggcagc	ttattgtgga	gctgaagaaa	2100
	gtatttgaaa	tcactcaatt	ttttcacatg	gagcaggaac	tggagtaaat	gcaatactgt	2160
60	gttgtaatat	cccaacaaaa	atcagacaaa	aaatggaaca	gacgtatttg	gacactgatg	2220
	gacttaagta	tgggaaggag	aaaaataggt	gtataaaatg	ttttccatga	gaaaccaaga	2280
	aacttacact	ggtttgacag	tggtcagtta	catgtcccca	cagttccaat	gtgcctgttc	2340
	actcacctct	cccttcccca	acccttctct	acttggtctg	tgtttttaag	tttgccttcc	2400
	cccaaatgtt	gattttttat	acagatctaa	agctcttttc	atttttact	gattaaatca	2460
	gtactgcagt	atttgatttaa	aaaaaaaata	gcagattttg	tgattcttgg	gacttttttg	2520
65	acgtaagaaa	tacttcttta	tttatgcata	ttcttcccac	agtgattttt	ccagcattct	2580
	tctgccatat	gccttttaggg	cttttataaa	atagaaaatt	aggcattctg	atatttcttt	2640

	agctgctttg	tgtgaaacca	tggtgtaaaa	gcacagctgg	ctgcttttta	ctgcttgtgt	2700
	agtcacgagt	ccattgtaat	catcacaatt	ctaaacccaa	ctaccaataa	agaaaacaga	2760
	catccaccag	taagcaagct	ctgttaggct	tccatgggta	gtggtagctt	ctctcccaca	2820
5	agttgtcctc	ctaggacaag	gaattatctt	aacaaactaa	actatccatc	acactacctt	2880
	ggtatgccag	cacctgggta	acagtaggag	attttataca	ttaatctgat	ctgtttaatc	2940
	tgatcgggtt	agtagagatt	ttatacat				

<210> 34

<211> 6011

10 <212> DNA

<213> Human

<400> 34

15

	acggggcgcc	ggacgacccg	cacatcttat	cctccacgcc	ccactcgcac	tcggagcggg	60
20	accgcccccg	actccccctc	gggcccggcca	ctcgaggagt	gaggagagag	gccgcccggc	120
	cggcttgagc	cgagcgcagc	accccccgcg	cccccgccca	gaagtttggg	tgaaccgggc	180
	tgccgggaga	aacttttttc	ttttttcccc	ctctcccggg	agagtctctg	gaggaggagg	240
	ggaactcccc	cggcccaagg	ctcgtgggct	cggggtcgcg	cggccgcaga	aggggcgggg	300
	tccgcccgcg	aggggaggcg	cccccgggga	cccagaggag	gggtgaggac	cgcgggctgc	360
25	tggtgcggcg	gcggcagcgt	gtgcccccg	caggggaggg	gccgccccgc	tccgggcccg	420
	gctgcgagga	ggaggcggcg	gcggcgaggg	aggatgtact	tggtggcggg	ggacaggggg	480
	ttggccggct	gcgggcacct	cctgggtctc	ctgctggggc	tgctgctgct	gccggcgcg	540
	tccggcaccc	gggcgctggt	ctgcctgccc	tgtgacgagt	ccaagtgcga	ggagcccagg	600
	aaccgcccgg	ggagcatcgt	gcagggcgct	tgccgctgct	gctacacgtg	cgcagccagg	660
	gggaacgaga	gctgcggcgg	caccttcggg	atttacggaa	cctgcgaccg	ggggctgcgt	720
30	tgtgtcatcc	gccccccgct	caatggcgac	tccctcaccg	agtacgaagc	gggcgtttgc	780
	gaagatgaga	actggactga	tgaccaactg	cttggtttta	aacctgcaa	tgaaaacctt	840
	attgtggctg	gcaatataat	caatgggaaa	tgtgaatgta	acaccattcg	aacctgcagc	900
	aatccctttg	agtttccaag	tcaggatatg	tgcccttcag	ctttaaaagag	aattgaagaa	960
35	gagaagccag	attgtcccaa	ggcccgtgtg	gaagtccagt	tctctccacg	ttgtcctgaa	1020
	gattctgttc	tgatcgaggg	ttatgtcctt	cctggggagt	gctgtccctt	acccagccgc	1080
	tgctgttgca	accccgcagg	ctgtctgcgc	aaagtctgcc	agccgggaaa	cctgaacata	1140
	ctagtgtcaa	aagcctcagg	gaagccggga	gagtgtgtgt	acctctatga	gtgcaaacca	1200
	gttttcggcg	tggaactgcag	gactgtggaa	tgccctactg	ttcagcagac	cgcgtgtccc	1260
40	ccggacagct	atgaaactca	agtcagacta	actgcagatg	gttgctgtac	tttgccaaca	1320
	agatgcgagt	gtctctctgg	cttatgtggg	ttccccgtgt	gtgaggtggg	atccactccc	1380
	cgcatagtct	ctcgtggcga	tgggacacct	ggaaagtgtc	gtgatgtctt	tgaatgtgtt	1440
	aatgatacaa	agccagccctg	cgtatttaac	aatgtggaat	attatgatgg	agacatgttt	1500
	cgaatggaca	actgtcgggt	ctgtcgatgc	caagggggcg	ttgccatctg	cttcacccgc	1560
45	cagtgtgggt	agataaaactg	cgagaggtac	tacgtgcccg	aaggagagtg	ctgcccagtg	1620
	tgtgaagatc	cagtgtatcc	ttttaataat	cccgttggct	gctatgccaa	tggcctgata	1680
	cttgcccacg	gagaccgggtg	gcgggaagac	gactgcacat	tctgccagtg	cgtcaacggg	1740
	gaacgccact	gcgttgccgac	cgtctgcgga	cagacctgca	caaaccctgt	gaaagtgcct	1800
	ggggagtgtt	gccctgtgtg	cgaagaacca	accatcatca	cagttgatcc	acctgcatgt	1860
50	ggggagtgtt	caaactgcac	tctgacacgg	aaggactgca	ttaatgggtt	caaacgcgat	1920
	cacaatgggt	gtcggacctg	tcagtgcata	aacaccaggg	aactatgttc	agaacgtaaa	1980
	caaggctgca	ccttgaactg	tcccttcggg	ttccttactg	atgccccaaa	ctgtgagatc	2040
	tgtgagtggc	gccccaggcc	caagaagtgc	agaccataaa	tctgtgacaa	gtattgtcca	2100
	cttgatttgc	tgaagaataa	gcacggctgt	gacatctgtc	gctgtaagaa	atgtccagag	2160
55	ctctcatgca	gtaagatctg	ccccttgggt	ttccagcagg	acagtcacgg	ctgtcttata	2220
	tgcaagtgca	gagaggcctc	tgcttcagct	ggggcaccca	tcctgtcggg	cacttgtctc	2280
	accgtggatg	gtcatcatca	taaaaatgag	gagagctggc	acgatgggtg	ccgggaatgc	2340
	tactgtctca	atggacggga	aatgtgtgcc	ctgatcacct	gcccgggtgc	tgccctgtgg	2400
	aaccccacca	ttcaccctgg	acagtgtctg	ccatcatgtg	cagatgactt	tgtgggtgcg	2460
	aagccagagc	tcagtatctc	ctccatttgc	cagccccctg	gaggagaata	ctttgtggaa	2520
60	ggagaaacgt	ggaacattga	ctcctgtact	cagtgcacct	gccacagcgg	acgggtgctg	2580
	tgtgagacag	agggtgtgccc	accgctgtct	tgccagaacc	cctcacgcac	ccaggattcc	2640
	tgctgcccac	agtgtacaga	tcaacctttt	cggccttcct	tgtcccgcga	taacagcgta	2700
	cctaattact	gcaaaaaatga	tgaaggggat	atatctcttg	cagctgagtc	ctggaagcct	2760
	gacgtttgta	ccagctgcata	ctgcatttat	agcgtaatta	gctgtttctc	tgagtctctc	2820
65	ccttctgtat	acctgtgaaag	cctgttcttg	agaaaaggcc	agtgttgtcc	ctactgcata	2880
	aaagacacaa	ttccaaagaa	ggtgggtgtg	cacttcagtg	ggaaggccta	tgccgacgag	2940

	gagcgggtggg	accttgacag	ctgcacccac	tgctactgcc	tgccaggcca	gaccctctgc	3000
	tcgacgctca	gctgcccccc	tctgccctgt	gttgagccca	tcaacgtgga	aggaagttgc	3060
	tgcccaatgt	gtccagaaat	gtatgtccca	gaaccaacca	atatacccat	tgagaagaca	3120
5	aaccatcgag	gagaggttga	cctggagggt	ccccgtgtgc	ccacgcctag	tgaaaatgat	3180
	atcgtccatc	tccctagaga	tatgggtcac	ctccaggtag	attacagaga	taacaggctg	3240
	cacccaagtg	aagattcttc	actggactcc	attgcctcag	ttgtggttcc	cataattata	3300
	tgctctctta	ttataatage	attcctatcc	atcaatcaga	agaaacagtg	gataccactg	3360
	ctttgctggt	atcgaacacc	aactaagcct	tcttccttaa	ataatcagct	agtatctgtg	3420
10	gactgcaaga	aaggaaccag	agtccagggt	gacagttccc	agagaatgct	aagaattgca	3480
	gaaccagatg	caagattcag	tggtctctac	agcatgcaaa	aacagaacca	tctacaggga	3540
	gacaatttct	accaaacagt	gtgaagaaa	gcaactagga	tgagggttca	aaagacggaa	3600
	gacgactaaa	tctgctctaa	aaagtaaaact	agaatttgtg	cacttgctta	gtggattgta	3660
	ttggattgtg	acttgatgta	cagcgctaag	accttactgg	gatgggctct	gtctacagca	3720
15	atgtgcagaa	caagcattcc	cacttttccct	caagataaact	gaccaagtgt	tttcttagaa	3780
	ccaaagtttt	taaagtgtgt	aagatatatt	tgctgtgtaag	atagctgtag	agatatttgg	3840
	ggtggggaca	gtgagtttgg	atggggaaa	gggtgggagg	gtggtgttgg	gaagaaaaat	3900
	tggtcagctt	ggctcgggga	gaaacctgggt	aacataaaa	cagttcagtg	gcccagaggt	3960
	tatttttttc	ctattgctct	gaagactgca	ctggttgctg	caaagctcag	gcctgaatga	4020
20	gcaggaaaca	aaaaaggcct	tgcgacccag	ctgccataac	caccttagaa	ctaccagacg	4080
	agcacatcag	aaccttttga	cagccatccc	aggtctaaag	ccacaagttt	cttttctata	4140
	cagtcaaca	tgcaagtaggc	agttaggaag	ccagagaaat	gcgatagcgg	catttctcta	4200
	aagcgggtta	ttaaggatat	atacagttac	actttttgct	gcttttattt	tcttccaagc	4260
	caatcaatca	gccagttcct	agcagagtca	gcacatgaac	aagatctaag	tcatttcttg	4320
25	atgtgagcac	tgagagctttt	tttttttaca	acgtgacagg	aagaggagg	agagggtgac	4380
	gaacaccagg	catttccagg	ggctatatatt	cactgtttgt	tgttgctttg	ttctgttata	4440
	ttgttggttg	ttcatagttt	ttgttgaagc	tctagcttaa	gaagaaaactt	tttttaaaaa	4500
	gactgtttgg	ggattctttt	tcttatttat	atactgattc	tacaaaaatag	aaactacttc	4560
	attttaattg	tatatatttc	aagcaccttt	gttgaagctc	aaaaaaaatg	atgcctcttt	4620
	aaacttttagc	aattatagga	gtatttatgt	aactatctta	tgcttcaaaa	aacaaaagta	4680
30	tttgtgtgca	tgtgtatata	atatatatat	atacatatat	atttatacac	atacaattta	4740
	tgttttccctg	ttgaatgtat	ttttatgaga	ttttaaccag	aacaaaggca	gataaacagg	4800
	cattccatag	cagtgccttt	gatcacttac	aaattttttg	aataacacaa	aatctcattc	4860
	tacctgcagt	ttaattggaa	agatgtgtgt	gtgagaglat	gtatgtgtgt	gtgtgtgtgt	4920
35	gtgtgtgcgc	gcgcacgcac	gccttgagca	gtcagcattg	cacctgctat	ggagaagggg	4980
	attcctttat	taaaatcttc	ctcatttgga	tttgctttca	gttggttttc	aatttgctca	5040
	ctggccagag	acattgatgg	cagttcttat	ctgcatact	aatcagctcc	tggtattttt	5100
	tttttttttt	tcaaacaatg	gtttgaaaca	actactggaa	tattgtccac	aataagctgg	5160
	aagtttgttg	tagtatgcct	caaatataac	tgactgtata	ctatagtgg	aacttttcaa	5220
40	acagccctta	gcacttttat	actaattaac	ccatttgctg	attgagtttt	cttttaaaaa	5280
	tgcttgttgt	gaaagacaca	gatacccgat	atgcttaacg	tgaaaagaaa	atgtgttctg	5340
	ttttgtaaa	gaactttcaa	gtattgttgt	aaatacttgg	acagaggttg	ctgaacttta	5400
	aaaaaaatta	atttattatt	ataatgacct	aatttattaa	tctgaagatt	aaccattttt	5460
	ttgtcttaga	atatcaaaaa	gaaaaagaaa	aaggtgttct	agctgtttgc	atcaaggaaa	5520
45	aaaaagattt	attatcaagg	ggcaatatatt	ttatcttttc	caaaaataaat	ttgttaatga	5580
	tacattacaa	aaatagattg	acatcagcct	gattagtata	aattttgttg	gtaattaatc	5640
	cattcctggc	ataaaaagtc	tttatcaaaa	aaaattgtag	atgcttgctt	tttgtttttt	5700
	caatcatggc	catattatga	aaatactaac	aggatatagg	acaaggtgta	aattttttta	5760
	ttattatttt	aaagatatga	tttatcctga	gtgtgtatc	tattactctt	ttactttggg	5820
50	tcctgttgtg	ctcttgtaaa	agaaaaatat	aatttccctga	agaataaaat	agatatatgg	5880
	cacttggagt	gcacatagat	tctacagttt	gtttttgttt	tcttcaaaaa	agctgtaaga	5940
	gaattatctg	caacttgatt	cttggcagga	aataaacatt	ttgagttgaa	atcaaaaaaa	6000
	aaaaaaaaaa	a					
55	<210>	34a					
	<211>	1036					
	<212>	DNA					
	<213>	Human					
60	<400>	34a					
	mylvagdrgl	agcghllvsl	lgllllpars	gtralvclpc	deskceepn	rpgsivqgvc	60
65	gccytcasgg	nescggtfgi	ygtcdrglrc	virpplngds	lteyeagvce	denwtddqll	120
	gfkpcnenli	agcniingkc	ecntirtcsn	pfefpsqdmc	lsalkrieee	kpdcskarce	180
	vqfsprcped	svliegyapp	geccplpsrc	vcnpagclrk	vcqpgnlnil	vskasgkpgc	240

5 ccdlyeckpv fgvdertvec ptvqqtacpp dsyetqvrllt adgcctlptr ceclsglclgf 300
 pvcevgstpr ivsrgdgtpr kccdvfecvn dtkpacvfnn veyydgdmfrr mdncrfrcrcq 360
 ggvaicftaq cgeinceryy vpegeccpvc edpvyppfnnp agcyanglil ahgdrwredd 420
 ctfcqcvnge rhcvatvcgq tctnrvkvpg eccpvceep iitvdppacg elsnctltrk 480
 dcingfkrdh ngcrteqcain tqelcserkq gctlncpfgf ltdaqnceic ecrprpkkr 540
 piicdkycpl gllknkhgdc icrcckcpel scskicplgf qqdshgcllc kcreasasag 600
 ppilsgtclt vdghhkhknee swhdgcrecy clngremcal itcpvpacgn ptihpgqccp 660
 scaddfvvqk pelstpsich apggeyfvveg etwnidsctq ctchsgrvlc etevcppllc 720
 10 qnpsrtqdsq cpqctdqpfr pslsrnnsvp nyckndegdi flaaeswkp d vctscicids 780
 viscfesescp svscerpvlr kgqccpycik dtipkkvvch fsgkayadee rwdldscthc 840
 yclggqtlcs tvscpplpcv epinvegsc pmcpemyvpe ptnipiekt n hrgevdlevp 900
 lwtpsendi vhlprdmghl qvdyrdnrhl psedssldsi asvvvpiiic lsiiaflfi 960
 nqkkqwipll cwyrtptkps slnnqlvsvd ckkgtrvqv d ssqrmlriae pdarfsgfys 1020
 15 mqkqnhlqad nfyqtv

<210> 35

<211> 716

<212> DNA

20 <213> Human

<400> 35

25 gcagtacctg gagggtcctg caggggggaaa gogaaccggg ccctgaagtc cgggggcagtc 60
 acccggggct cctgggcccgc tctgccgggc tggggctgag cagcgatcct gctttgtccc 120
 agaagtcagc agggatcagc cccagaacac accctcctcc ccgggacgcc gcagctttct 180
 ggaggctgag gaaggcatga agagtgggct ccacctgctg gccgactgag aaaagaattt 240
 30 ccagaactcg gtcctatttt acagattgag aaactatggt tcaagaagag aggacggggc 300
 ttgagggaat ctctgtattc tccttatatg acctcaaact gaccatacta aacagtgtag 360
 aaggctcttt taaggctcta aatgtcaggg tctcccatcc cctgatgcct gacttgtaca 420
 gtcagtgtgg agtagacggt ttctccacc cagggttgac tcagggggat gatctgggtc 480
 ccattctggt cttaaagacc caaacaaggg ttttttcagc tccaggatct ggagcctcta 540
 35 tctggttagt gtcgtaacct ctgtgtgcct cccgttacc catctgtcca gtgagctcag 600
 ccccatcca cctaacaggg tggccacagg gattactgag ggtaagacc ttagaactgg 660
 gtctagcacc cgataagagc tcaataaatg ttgttccttt ccacatcaaa aaaaaa

<210> 36

<211> 395

<212> DNA

40 <213> Human

<400> 36

45 ccaatacttc attcttcatt ggtggagaag attgtagact tctaagcatt ttccaaataa 60
 aaaagctatg atttgatttc caacttttaa acattgcatg tcctttgcca ttactacat 120
 tctccaaaaa aaccttgaaa tgaagaaggc cacccttaaa atacttcaga ggctgaaaat 180
 atgattatta cattggaatc ctttagccta tgtgatattt ctttaacttt gcactttcac 240
 gccagtaaaa accaaagtca gggtaaccaa tgtcatttta caaaatgtta aaacccta 300
 50 tgcagttcct tttttaaatt atttttaaga ttacttaaca acattagaca gtgcaaaaaa 360
 agaagcaagg aaagcattct taattctacc atcct

<210> 37

<211> 134

<212> DNA

55 <213> Human

<400> 37

60 ccctcgagcg gccgcccggg caggtaacttt taccacggaa ttgttcactt gactttaaga 60
 aaccataaaa gctgctggc tttcagcaac aggccatata acaccatggt gacttccat 120
 aaggacacc gtgt

<210> 38

<211> 644

<212> DNA

65

<213> Human

<400> 38

```

5  aagcctgttg  tcatggggga  ggtggtggcg  cttggtggcc  actggcggcc  gaggtagagg  60
   cagtggcgct  tgagttggtc  gggggcagcg  gcagatttga  ggcttaagca  acttcttccg  120
   gggaagagtg  ccagtgcagc  cactgttaca  attcaagatc  ttgatctata  tccatagatt  180
   ggaatatttg  tgggccagca  atcctcagac  gcctcactta  ggacaaatga  ggaaactgag  240
10  gcttggtgaa  gttacgaaac  ttgtccaaaa  tcacacaaact  tgtaaagggc  acagccaaga  300
   ttcagagcca  ggctgtaaaa  attaaaatga  acaaattacg  gcaaagtttt  aggagaaaaga  360
   aggatgttta  tgttccagag  gccagtcgtc  cacatcagtg  gcagacagat  gaagaaggcg  420
   ttgcgaccgg  aaaatgtagc  ttcccggtta  agtaccttgg  ccatgtagaa  gttgatgaat  480
   caagaggaat  gcacatctgt  gaagatgctg  taaaaagatt  gaaagctgaa  aggaagttct  540
15  tcaaaggctt  ctttgaaaaa  actggaaaga  aagcagttaa  agcagtttct  gtgggtctaa  600
   gcagatggac  tcagaggttg  tggatgaaaa  actaaggacc  tcat

```

<210> 39

<211> 657

<212> DNA

20 <213> Human

<400> 39

```

25  ctttttgttt  gggttttcca  atgtagatgt  ctgagtgaaa  tgtgcagata  tactttgttc  60
   cttatatggt  caccagtgtt  aattatggac  aaatacatta  aaacaagggg  tcctggccca  120
   gcctcccata  taatctcttt  gatactcttg  gaatctaagt  ctgaggagcg  atttctgaat  180
   tagccagtgt  tgtaccaact  ttctgttagg  aattgtatta  gaataacctt  tctttttcag  240
   acctgctcag  tgagacatct  tggggaatga  agtaggaaaa  tagacatttg  gtggaaaaac  300
30  agcaaaatga  gaacattaaa  aagactcatt  caagtatgag  tataaagggc  atggaaattc  360
   tggtcctttg  agcaaaatga  gaagaaaaaa  ttctgctcag  cagtattcac  tgtgttaaga  420
   ttttttgttt  tttacacgaa  tggaaaaatg  atgtgtaagt  ggtatagatt  ttaatcagct  480
   aacagtcact  ccagagattt  tgatcagcac  caattcctat  agtagtaagt  atttaaaagt  540
   taagaaatac  tactacattt  aacattataa  agtagagtgc  tggacataac  tgaaaattag  600
35  atgtttgctt  caatagaaat  ttgttcccac  ttgtattttc  aacaaaatta  tcggaac

```

<210> 40

<211> 1328

<212> DNA

40 <213> Human

<400> 40

```

45  acaatttttaa  aataactagc  aattaatcac  agcatatcag  gaaaaagtac  acagtgaagt  60
   ctggttagtt  tttgtaggct  cattatggtt  agggctcgta  agatgtatat  aagaacctac  120
   ctatcatgct  gtatgtatca  ctcatcccat  tttcatgttc  catgcatact  cgggcacatc  180
   gctaatatgt  atccttttaa  gcactctcaa  ggaaacaaaa  gggcctttta  tttttataaa  240
   ggtaaaaaaaa  attccccaaa  tattttgcac  tgaatgtacc  aaagggtgaag  ggacattaca  300
   atatgactaa  cagcaactcc  atcacttgag  aagtataata  gaaaatagct  tctaaatcaa  360
50  acttccttca  cagtgcogtg  tctaccacta  caaggactgt  gcatctaagt  aataattttt  420
   taagattcac  tatatgtgat  agtatgatat  gcattttatt  aaaatgcatt  agactctctt  480
   ccatccatca  aatactttac  aggatggcat  ttaatacaga  tatttcgtat  ttccccact  540
   gctttttatt  tgtacagcat  cattaaacac  taagctcagt  taaggagcca  tcagcaacac  600
   tgaagagatc  agtagtaaga  attccatttt  cctcatcag  tgaagacacc  acaaattgaa  660
55  actcagaact  atatttctaa  gcctgcattt  tcactgatgc  ataattttct  tagtaatttt  720
   aagagacagt  ttttctatgg  catctccaaa  actgcattgc  atcactagtc  ttacttctgc  780
   ttaattttat  gagaagggtat  tcttcatttt  aattgctttt  gggattactc  cacatctttg  840
   tttatttctt  gactaatcag  attttcaata  gagtgaagtt  aaattggggg  tcataaaaagc  900
   attggattga  catatggttt  gccagcctat  ggggtttacag  gcattgcccc  aacattttct  960
   tgagatctat  atttataagc  agccatggaa  ttccattatt  gggatgttgg  caatcttaca  1020
60  ttttatagag  gtcatatgca  tagttttcat  aggtgttttg  taagaactga  ttgctctcct  1080
   gtgagttaag  ctatgtttac  tactgggacc  ctcaagagga  ataccactta  tgttacactc  1140
   ctgcactaaa  ggcacgtact  gcagtgtgaa  gaaatgttct  gaaaaagggg  tatagaaatc  1200
   tggaaataag  aaaggaagag  ctctctgtat  tctataattg  gaagagaaaa  aaagaaaaac  1260
65  ttttaactgg  aaatgttagt  ttgtacttat  tgatcatgaa  tacaagtata  tatttaattt  1320
   tgaaaaaa

```

<210> 41
 <211> 987
 <212> DNA
 <213> Human

5

<400> 41

10	aacagagact	ggcacaggac	ctcttcattg	caggaagatg	gtagtgtagg	caggtaacat	60
	tgagctcttt	tcaaaaaaagg	agagctcttc	ttcaagataa	ggaagtggta	gttatgggtg	120
	taaccccccg	ctatcagtc	ggatgggttg	cacccctcct	gctgtaggat	ggaagcagcc	180
	atggagtggg	agggaggcgc	aataagacac	ccctccacag	agcttggcat	catgggaagc	240
	tggttctacc	tcttcctggc	tcctttgttt	aaaggcctgg	ctgggagcct	tccttttggg	300
	tgtctttctc	ttctccaacc	aacagaaaag	actgctcttc	aaaggtggag	ggtcttcatg	360
15	aaacacagct	gccaggagcc	caggcacagg	gctggggggc	tggaaaaagg	agggcacaca	420
	ggaggaggga	ggagctggta	gggagatgct	ggctttacct	aaggtctcga	aacaaggagg	480
	gcagaatagg	cagaggcctc	tccgtcccag	gcccattttt	gacagatggc	gggacggaaa	540
	tgcaatagac	cagcctgcaa	gaaagacatg	tgttttgatg	acaggcagtg	tggccgggtg	600
	gaacaagcac	aggccttgga	atccaatgga	ctgaatcaga	accctaggcc	tgccatctgt	660
20	cagccgggtg	acctgggtca	atttttagcct	ctaaaagcct	cagtctcctt	atctgcaaaa	720
	tgaggcttgt	gatacctgtt	ttgaagggtt	gctgagaaaa	ttaaagataa	gggtatccaa	780
	aatagtctac	ggccatacca	ccctgaacgt	gcctaattctc	gtaagctaag	cagggtcagg	840
	cctggtttagt	acctggatgg	ggagagtatg	gaaaacatac	ctgccgcag	ttggagttgg	900
	actctgtctt	aacagttagc	tggcacacag	aaggcactca	gtaaatactt	gttgaataaa	960
25	tgaagtagcg	atttgggtgtg	aaaaaaa				

<210> 42
 <211> 956
 <212> DNA
 <213> Human

30

<400> 42

35	eggacgggtg	ggcggacgcy	tgggtgcagg	agcagggcgg	ctgccgactg	ccccaaccaa	60
	ggaaggagcc	cctgagtcog	cctgcgcctc	catccatctg	tccggccaga	gccggcatcc	120
	ttgcctgtct	aaagccttaa	ctaagactcc	cgccccgggc	tggccctgtg	cagaccttac	180
	tcaggggatg	tttacctgtt	gctcgggaag	ggaggggaag	gggccgggga	gggggcacgg	240
	caggcgtgtg	gcagccacac	gcaggcggcc	agggcgggcca	gggacccaaa	gcaggatgac	300
	cacgcacctc	cacgccactg	cctccccoga	atgcatttgg	aaccaaaagtc	taaaactgagc	360
40	tcgcagcccc	cgcgccctcc	ctccgcctcc	catcccgttt	agcgctctgg	acagatggac	420
	gcaggccctg	tcagccccc	agtgcgctcg	ttccgggtccc	cacagactgc	cccagccaac	480
	gagattgctg	gaaaccaagt	caggccaggt	gggcggaaca	aagggccagg	tgccgctgtg	540
	ggggaacgga	tgctccgagg	actggactgt	ttttttcaca	catcggttgc	gcagcgggtg	600
	gaaggaaaag	cagatgtaaa	tgatgtgttg	gtttacaggg	tatatattttg	ataccttcaa	660
	tgaattaatt	cagatgtttt	acgcaaggaa	ggacttacct	agtattactg	ctgctgtgct	720
45	tttgatctct	gcttaccgtt	caagaggcgt	gtgcaggccg	acagtcgggtg	accccatcac	780
	tcgcaggacc	aagggggcgg	ggactgctgg	ctcacgcccc	gctgtgtcct	ccctccctc	840
	ccttccttgg	gcagaatgaa	ttcgatgcgt	attctgtggc	cgccatctgc	gcagggtggt	900
	ggtattctgt	catttacaca	cgctgttcta	attaaaaagc	gaattatact	ccaaaa	

50

<210> 43
 <211> 536
 <212> DNA
 <213> Human

55

<400> 43

60	aaataaacac	ttccataaca	ttttgttttc	gaagtctatt	aatgcaatcc	cacttttttc	60
	cccctagttt	ctaaatgtta	aagagagggg	aaaaaaggct	caggatagtt	ttcacctcac	120
	agtgttagct	gtctttttatt	ttactcttgg	aaatagagac	tccattaggg	ttttgacatt	180
	ttgggaaccc	agttttacca	ttgtgtcagt	aaaacaataa	gatagtttga	gagcatatga	240
	tctaaataaa	gacatttgaa	gggttagttt	gaattctaaa	agtaggtaat	agccaaatag	300
	cattctcatc	ccttaacaga	caaaaactta	tttgtcaaaa	gaattagaaa	aggtgaaaat	360
	atTTTTTcca	gatgaaactt	gtgccacttc	caattgacta	atgaaataca	aggagacaga	420
	ctggaaaaag	tgggttatgc	caccttttaa	accctttctg	gtaaatatta	tggtagctaa	480
65	aggggtgggtt	ccccggcacc	tggacctgga	caggtagggg	tccgtgggtta	accagt	

<210> 44
 <211> 1630
 <212> DNA
 <213> Human

5

<400> 44

10	ggggaggggac	gagtatggaa	ccctgaaggt	agcaagtcca	ggcactggcc	tgaccatccg	60
	gctccctggg	caccaagtcc	caggcaggag	cagctgtttt	ccatcccttc	ccagacaagc	120
	tctatttttta	tcacaatgac	ctttagagag	gtctcccagg	ccagctcaag	gtgtcccact	180
	atcccctctg	gaggggaagag	gcaggaaaat	tctcccggg	tccctgtcat	gctactttct	240
	ccatcccagt	tcagactgtc	caggacatct	tatctgcagc	cataagagaa	ttataaggca	300
	gtgatttccc	ttaggcccag	gacttggggc	tccagctcat	ctgttccctc	tgggcccatt	360
15	catggcaggt	tctgggctca	aagctgaact	ggggagagaa	gagatacaga	gctaccatgt	420
	gactttacct	gattgccctc	agtttgggg	tgcttattgg	gaaagagaga	gacaaagagt	480
	tacttgttac	gggaaatatg	aaaagcatgg	ccaggatgca	tagaggagat	tctagcaggg	540
	gacaggattg	gctcagatga	cccctgagg	ctcttccagt	cttgaaatgc	attccatgat	600
	attaggaagt	cgggggtggg	tgggtgggtg	gggctagtgt	ggtttgaatt	tagggggccga	660
20	tgagcttggg	tacgtgagca	gggtgttaag	ttagggctctg	cctgtatttc	tgggtcccctt	720
	ggaaatgtcc	ccttcttcag	tgtcagacct	cagtcccagt	gtccatatcg	tgcccagaaa	780
	agtagacatt	atcctgcccc	atcccttccc	cagtgcactc	tgacctagct	agtgcctggg	840
	gcccagtgac	ctgggggagc	ctggctgcag	gccctcactg	gttccctaaa	ccttgggtggc	900
	tgtgattcac	gtccccagg	gggactcagg	gaggaatatg	gctgagttct	gtagtttcca	960
25	gagttggctg	gtagagcctt	ctagaggttc	agaatattag	cttcaggatc	agctgggggt	1020
	atggaattgg	ctgaggatca	aacgtatgta	ggtgaaagga	taccaggatg	ttgctaaagg	1080
	tgagggacag	tttgggtttg	ggacttacca	gggtgatgtt	agatctggaa	cccccaagtg	1140
	aggctggagg	gagttaaggt	cagtatggaa	gatagggttg	ggacagggtg	ctttggaatg	1200
	aaagagtgc	cttagagggc	tccttggggc	tcaggaatgc	tctgtctgct	gtgaagatga	1260
30	gaaggtgctc	ttactcagtt	aatgatgagt	gactatattt	accaaagccc	ctacctgctg	1320
	ctgggtccct	tgtagcacag	gagactgggg	ctaaggggcc	ctcccaggga	agggacacca	1380
	tcaggcctct	ggctgaggca	gtagcataga	ggatccattt	ctacctgcac	ttcccagagg	1440
	actagcagga	ggcagccttg	agaaaccggc	agttcccaag	ccagcgccctg	gctgttctct	1500
	cattgtcact	gccctctccc	caacctctcc	tctaaccac	tagagattgc	ctgtgtctct	1560
35	cctcttgcc	cttgtagaat	gcagctctgg	ccctcaataa	atgcttctctg	cattcatctg	1620
	caaaaaaaaa						

<210> 45
 <211> 169
 <212> DNA
 <213> Human

40

<400> 45

45	tcttttgcct	ttagcttttt	atttttgtat	taacaggagt	cttattacac	ataggtctga	60
	taaaactgg	ttatgatctt	cagtctgatt	ccagtgtctg	ataactagat	aacgtatgaa	120
	ggaaaaacga	cgacgaacaa	aaaagtaagt	gcttggaaga	cttagttga		

<210> 46
 <211> 769
 <212> DNA
 <213> Human

50

<400> 46

55	tgcaggctcat	atttactatc	ggcaataaaa	ggaagcaaag	cagtattaag	cagcgggtgga	60
	atttgcgcct	ttcacttttt	ataaagtgtc	acataaaatg	tcatatttcc	aaatttaaaa	120
	acataactcc	agttcttacc	atgagaacag	catgggtgatc	acgaaggatc	ttcttgaaaa	180
	aaacaaaaac	aaaaacaaaa	aacaatgatc	tcttctgggt	atcacatcaa	atgagatata	240
60	aaggtgtact	aggcaatctt	agagatcttg	caacttattt	tatatataag	gcatctgtga	300
	ccaagagacg	ttatgaatta	aatgtacaaa	tgtattatgt	ataaatgtat	taaatgcaag	360
	cttcatataa	tgacaccaat	gtctctaagt	tgctcagaga	tcttgactgg	ctgtggccct	420
	ggccagctcc	tttcctgata	gtctgattct	gccttcatat	ataggcagct	cctgatcatc	480
	catgccagtg	aatgagaaaa	caagcatgga	atatataaac	tttaacatta	aaaaatgttt	540
	tattttgtaa	taaaatcaaa	tttcccattg	aaaccttcaa	aaactttgca	gaatgaggtt	600
65	ttgatataatg	tgtacaagta	gtaccttctt	agtgcagaaa	aacatcatta	tttctgtctg	660
	cctgcctttt	tgtttttaaa	aatgaagact	atcattgaaa	caagtttgtc	ttcagtatca	720

ggacatgttg acggagagga aaggtaggaa agggttaggg atagaagcc

<210> 47
 <211> 2529
 <212> DNA
 <213> Human

<400> 47

10 tttagttcat agtaatgtaa aaccatttgt ttaattctaa atcaaatac tttcacaaca 60
 gtgaaaatta gtgactgggt aaggtgtgcc actgtacata tcatcatttt ctgactgggg 120
 tcaggacctg gtcctagtcc acaagggtgg caggaggagg gtggaggcta agaacacaga 180
 aaacacacaa aagaaaggaa agctgccttg gcagaaggat gaggtggtga gcttgccgag 240
 ggatggtggg aagggggctc cctgttgggg ccgagccagg agtcccaagt cagctctcct 300
 15 gccttactta gtcctggca gagggtgagt ggggacctac gaggttcaaa atcaaattggc 360
 atttggccag cctggcttta ctaacaggtt cccagagtgc ctctgttggc tgagctctcc 420
 tgggctcact ccatttcatt gaagagtcca aatgattcat ttctctaccc acaacttttc 480
 attattcttc tggaaaccca tttctgttga gtccatctga cttaagtcc ctctccctcc 540
 actagttggg gccactgcac tgaggggggt cccaccaatt ctctctagag aagagacact 600
 20 ccaggagccc ctgcaacttt gcggatttcc agaaggtgat aaaaagagca ctcttgagtg 660
 ggtgcccgag aatgttttaa atctatcagg cacactataa agctggtggt ttcttccctac 720
 caagtggatt cggcatatga accactact caatacttta tattttgtct gtttaaacac 780
 tgaactctgg tgttgacagg tacaaggag aagagatggg gactgtgaag aggggagggc 840
 25 ttccctcatc ttctcaaga tctttgttcc cataaactat gcagtcataa ttgagaaaaa 900
 gcaatagatg gggcttccca ccatttgttg gttattgctg gggtagcca ggagcagtg 960
 ggatggcaaa gtaggagaga ggcccagagg aaagcccatc tccctccagc tttgggggtct 1020
 ccagaaagag gctggatttc tgggatgaag cctagaaggc agagcaagaa ctgttccacc 1080
 aggtgaacag tctactctgc ttggtaccat agtccctcaa taagattcag aggaagaagc 1140
 ttatgaaact gaaaatcaaa tcaaggtatt gggaagaata atttccctc gattccacag 1200
 30 gaggaagac cacacaatat cattgtgctg gggctccca aggcctgccc acctggcttt 1260
 acaaatcatc aggggttgcc tgcttgccag tcacatgctt ccctggtttt agcacacata 1320
 caaggagttt tcagggaact ctatcaagcc atacaaaaat cagggtcaca tgtgggtttc 1380
 ccctttcctt gcctcttcat aaaagacaac ttggcttctg aggatggtgg tcttttgcag 1440
 gcagttgggc tgacctgaca aagccccag tttctgtgg caggttctgg gagaggatgc 1500
 35 attcaagctt ctgcagccta ggggacagg ctgcttgttc agttattact gcctcggagc 1560
 tccaaatccc accaaagtcc tgactccagg tctttcctaa tgcacagtag tcagtctcag 1620
 cttcggcagt attctcggct gtatgttctc tggcagagag aggcagatga acatagtttt 1680
 agggagaaag ctgatgggaa acctgtgagt taagccacat gtctcaccag gaataattta 1740
 40 tgccaggaaa ccaggaagtc attcaagttg ttctctgagg ccaaagacac tgagcacagc 1800
 ccagagccaa taaaagatct ttgagtctct ggtgaattca cgaagtgacc ccagctttag 1860
 ctactgcaat tatgattttt atgggacagc aatttcttgc atctctacag aggaagaaga 1920
 gggggagtggt gaggggaagg aaagagaaca gagcggcact gggatttgaa aggggaacct 1980
 ctctatctga ggagccccca ctggcttcag aagcaactta ccaaggggta tttaaagaca 2040
 45 tgaaaatttc cagaaatacc atttggtgca tcccttgtt tctgtaatat taaactcagg 2100
 tgaaattata ctctgacagt ttctctcttt ctgcctcttc cctctgcaga gtcaggacct 2160
 gcagaaactg ctgaaacaag atttcatggt gtcacccatg agagatgact caatgccaa 2220
 gctgaagtt atagagtgtt tacagcgggt gcgatattca ggggtcatcg ccaactggtc 2280
 tcgagttcca aagctctgat gaagaaacaa gactccttga tgtgttactg atcccactga 2340
 50 ttccaggagt caagattagc caggaagcca aacaccagga gttgggggtg cacgtcacca 2400
 gtccagagcc ctgccacgga tgtacgcagg agcccagcat taggcaatca ggagccagaa 2460
 catgatcacc agggccacaa ataggaagag gcgtgacagg aactgctcgt ccacatacct 2520
 ggggtgtcc

<210> 48
 <211> 1553
 <212> DNA
 <213> Human

<400> 48

60 tttttttttt tttttgattt ctgggacaat taagctttat ttttcatata tatatatatt 60
 ttcataatata tatatacata catatataaa ggaaacaatt tgcaaattta cacacctgac 120
 aaaaccatata atacacacat atgtatgcat acacacagac agacacacac acccgaagct 180
 ctaggcaggc ccgtttttcca tccctaagta ccattctctc atttggggcc ttctagggtt 240
 65 ggggccctga gcttgggttg tagaagtttg gtgctaatat aaccatagct ttaatccca 300
 tgaaggacag tgtagacctc atctttgtct gctcccgcgt gcctttcagt tttacgtgat 360

5 ccatcaagag ggctatggga gccaaagtga caccggggat tgaggctaatt tcacctgaac 420
 tcgaaaacag cgcccagctt cctcaccgca ggcacgcgtc ttttcttttt ttttctctga 480
 gacggagctc cgctgtgttg cccaggctgg agtgcagtg caccgtctcg gctcactgca 540
 agctccacct cctggattca taccattctc ctgcttcagc cttccgagta gctgggacta 600
 taggtgccaa ccactacgcc tagctaattt tttttgtat ttttagtaga gacagggttt 660
 caccgtgtta gccaggatgg tctcgctcctg actttgtgat ccgccgcct cggcctccca 720
 aagtgtctggg attacaggcg tgagccacca cacctggccc cggcacgtat cttttaagga 780
 atgacaccag ttcctggctt ctgaccaaag aaaaaatgtc acaggagact ttgaagaggc 840
 10 agacaggagg gtggtggcag caacactgca gctgcttctg gatgctgctg ggtgctctc 900
 cggagcgggt gtgaacagcg cacttcaaca tgagcaggcg cctggctccg gtgtgtcctc 960
 acttcagtg tgacactgga tgggtgaagc cagcctttgg ggcaggaaac cagctcagag 1020
 aggctaccca gctcagctgc tggcaggagc caggtattta cagccataat gtgtgtaaa 1080
 aaaaaacacg ttctgcaaga aactctccta cccgctcggg agactggggc tccttgcttg 1140
 15 ggatgagctt cactcaacgt ggagatggtg gtggactggt ccctgaaaag cgggccttg 1200
 agggccaagt gaggtcctca ggtcctaac ccagtggccc tctgaaaggg ggtgtgcagg 1260
 cgaggggagc aggaggcttc tctctagtcc ctttgagggc tttggctgag agaagagtga 1320
 gcagggagct gggaatggtc caggcagggg agggagctga agtgattcgg ggctaatagcc 1380
 tcagatcgat gtatttctct ccctggtctc ccggagccct cttgtcaccg ctgctgccct 1440
 20 gcagggaggc catctcttct gggagcttat ctgacttaac ttcaactaca agttcgctct 1500
 tacgagaccg ggggtagcgt gatctcctgc ttccctgagc gcctgcacgg cag

<210> 49

<211> 921

<212> DNA

25 <213> Human

<400> 49

30 ctgtggctccc agctactcag gaggctgagg cgggaggatt gcttgagccc aggagttgga 60
 tggtgcagtg agccaagatc gcaccattgc cctccactct gggccacgga gcaataacct 120
 gtctcagaaa acaacaaca aaaagcagaa acgctgaagg ggtcggttta cgggaaaacc 180
 gctctgcaga acacttggct actcctaccc cagatcagtg gacctgggaa tgagggttg 240
 tcccgggagg cttttctcca agctgttgcc accagaccg ccattgggaa cctggccaca 300
 35 gaagcctccc ggggagttag ccagagcctg gaccgctgtg ctgatgtgtc tggggtggag 360
 ggaggggtggg gagtgtgcaa ggtgtgtgt gtgccgggg ggtgttcatt ggcaagcatg 420
 tgcgtgcctg tgtgtgtgcg tgccctccc ctgcagccgt cgggtggtatc tccctccagc 480
 cccttcgcca ccttctgagc attgtctgtc cactgtagac tgcccagaga cagcagagct 540
 ccactgtggt ttaaggggag acctttccct ggacctggg gtctcgccgt atctcatgac 600
 caggtgctaa atgacccgac atgcatcacc tgcctttcga tgaccaacct ccctgtcccc 660
 40 gtcccgtgta cctgcccccg tggcgtctca cggatgatgc tgctcctgac attggtgttc 720
 actgtagcaa actacattct ggatgggaat ttcatgtac atgtgtggca tgtggaaaat 780
 ttcaaataaa atggacttga tttagaaagc caaaaagctg tgtggctcct ccagcacgga 840
 tactttgacc tcttgacct aacccttcc ttgggtccga ggtggttagc tttgttact 900
 45 tcagatgggt gggggcgggt g

<210> 50

<211> 338

<212> DNA

50 <213> Human

<400> 50

55 atgatctatc tagatgccct accgtaaaa caaaacacaa aaccctactg actcattccc 60
 tcccttccag atattacccc atttctctac ttccattgt agccaaactt tccaaaaatt 120
 catgtttctgt cttcatttcc tcatgttcaa cccacctgt cttagctacc acccctcagt 180
 aacgacctag cctgggtaga aacaaatgtc agcatgata catactcaat gatccttcgt 240
 cactgttgctc attgtcatca ttccatggcc ttactttccc tctcagcgcc atttgctaca 300
 gtaagaaact ttttttcttg aattcttggg tctcttgg

60 <210> 51

<211> 1191

<212> DNA

<213> Human

65 <400> 51

	ctagcaagca	ggtaaacgag	ctttgtacaa	acacacacag	accaacacat	ccggggatgg	60
	ctgtgtgttg	ctagagcaga	ggctgattaa	acactcagtg	tgttggctct	ctgtgccact	120
	cctggaaaat	aatgaattgg	gtaaggaaca	gttaataaga	aaatgtgcct	tgctaactgt	180
5	gcacattaca	acaaagagct	ggcagctcct	gaaggaaaag	ggcttgtgcc	gctgccgttc	240
	aaacttgtca	gtcaactcat	gccagcagcc	tcagcgtctg	cctccccagc	acaccctcat	300
	tacatgtgtc	tgtctggcct	gatctgtgca	tctgctcgga	gacgctcctg	acaagtcggg	360
	aattttctcta	tttctccact	gggtgcaaaga	gcggattttct	ccctgcttct	cttctgtcac	420
	ccccgctcct	ctccccaggg	aggctccttg	atztatggta	gctttggact	tgcttccccg	480
10	tctgactgtc	cttgacttct	agaatggaag	aagctgagct	ggtgaaggga	agactccagg	540
	ccatcacaga	taaaaagaaa	atacaggaag	aaatctcaca	gaagcgtctg	aaaatagagg	600
	aagacaaaact	aaagcaccag	caatttgaaga	aaaaggcctt	gagggagaaa	tggtctctag	660
	atggaatcag	cagcggaaaa	gaacaggaag	agatgaagaa	gcaaaatcaa	caagaccagc	720
	accagatcca	ggttctagaa	caaagtatcc	tcaggcttga	gaaagagatc	caagatcttg	780
15	aaaaagctga	actgcaaatc	tcaacgaagg	aagaggccat	tttaaagaaa	ctaaagtcaa	840
	ttgagcggac	aacagaagac	attataagat	ctgtgaaagt	ggaaagagaa	gaaagagcag	900
	aagagtcaat	tgaggacatc	tatgctaata	tccttgacct	tccaaagtcc	tacataacct	960
	ctaggttaag	gaaggagata	aatgaagaaa	aagaagatga	tgaacaaaat	aggaaagctt	1020
	tatatgccat	ggaaattaaa	gttgaaaaag	acttgaagac	tgagagaaagt	acagttctgt	1080
20	cttccaatac	ctctggccat	cagatgactt	taaaaggtag	aggagtaaaa	gtttaagatg	1140
	atggggcaaaa	gtccagtgtg	ttcagtaaag	tgctaatac	aagttggagg	t	

<210> 52

<211> 1200

<212> DNA

25 <213> Human

<400> 52

30	aacagggact	ctcactctat	caaccccagg	ctggagtcgg	gtgcgcccac	cctgggtccc	60
	tgcaacctcc	gcctcccagg	ctcaagcaac	tctcctgcct	cagtcgctct	agtagctggg	120
	actacaggca	cacaccacca	tgcccagcca	atttttgcat	ttttttaga	gacagggttt	180
	cgccttctgt	ccaggccggc	atcatatact	ttaaatcatg	cccagatgac	tttaataacct	240
	aatacaatat	atcagggttg	tttaaaaaata	attgcttttt	tattattttt	gcattttttgc	300
35	accaacctta	atgctatgta	aatagttgtt	atactgttgc	ttaacaacag	tatgacaatt	360
	ttggcttttt	ctttgtatta	ttttgtattt	ttttttttta	ttgtgtggtc	tttttttttt	420
	ttctcagtg	tttcaattcc	tccttggttg	aatccatgga	tgcaaaaccc	acagatatga	480
	agggctggct	atatatgcat	tgatgattgt	cctattatat	tagttataaa	gtgtcattta	540
	atatgtagt	aaagtttatg	tacagtggaa	agagtagttg	aaaacataaa	catttggacc	600
40	tttcaagaaa	ggtagcttgg	tgaagttttt	caccttcaaa	ctatgtccca	gtcagggctc	660
	tgctactaat	tagctataat	ctttgcacaa	attacatcac	ctttgagtct	cagttgcctc	720
	acctgtaaaa	tgaaagaact	ggatactctc	taaggtcact	tccagccctg	tcattctata	780
	actctgttat	gctgaggaag	aaattcacat	tgtgttaact	gtatgagtca	aactgaaaaa	840
	gattattaaa	gtgggaaaaa	gccaattgct	tctcttagaa	agctcaacta	aatttgagaa	900
45	gaataatctt	ttcaattttt	taagaatttta	aatatttttt	agggtttgac	ctattttatt	960
	agagatgggg	tctcactctg	tcacccagac	tgaggtacag	tggcacaatc	atagctcact	1020
	gctgcctcaa	attcatgggc	tcaagtgatc	ctcctgcctc	tgccctccaga	gtagctgcga	1080
	ctatgggcat	gtgccaccac	gcctggctaa	catttgtatt	gacctattta	tttattgtga	1140
	tttatatctt	tttttttttt	tctttttttt	tttttttcaa	aatcagaaat	acttattttg	1200

50 <210> 53

<211> 989

<212> DNA

<213> Human

55 <400> 53

60	aagocaccac	tcaaaacttc	ctatacat	tcacagcaga	gacaagtga	catttatttt	60
	tatgcctttc	ttcctatgtg	tatttcaagt	cttttttcaa	acaaggcccc	aggactctcc	120
	gattcaatta	gtccttgggc	tggtcgactg	tgcaggagtc	cagggagcct	ctacaaatgc	180
	agagtgaact	tttaccacaa	taaaccctag	atacatgcaa	aaagcaggac	ccttctcca	240
	ggaatgtgcc	atttcagatg	cacagcacc	atgcagaaaa	gctggaattt	tccttggaac	300
	cgactgtgat	agaggtgctt	acatgaacat	tgctactgtc	tttctttttt	tttgagacag	360
	gttttcgctt	tgcccaggct	gagtgcattg	cgatgatctc	ctcactgcaa	ttccacctcc	420
	aggttcaagc	attctcctgc	tcagcctcct	agtagctggg	ttacaggcac	tgccaccatg	480
65	ccgggtcaatt	ttgtattttt	gtagagatgg	atttctccat	ttggtcaggc	ggtctcgaac	540
	cccaacctca	gtgatctgcc	acctcagcct	cctaagtgtt	ggattacagg	atgagccacc	600

	cgaccggcca	ctactgtctt	tctttgaccc	ttccagtttc	gaagataaag	aggaaataat	660
	ttctctgaag	tacttgataa	aattttccaaa	caaaacacat	gtccacttca	ctgataaaaa	720
	atttaccgca	gtttggcacc	taagagtatg	acaacagcaa	taaaaagtaa	tttcaaagag	780
5	ttaagatttc	ttcagcaaaa	tagatgattc	acatcttcaa	gtcctttttg	aatcagttta	840
	ttaatattat	tctttcctca	tttccatctg	aatgactgca	gcaatagttt	tttttttttt	900
	tttttttttt	ttgcgagatg	gaatctcgct	ctgtcgccca	gcgggagtg	actggcgcaa	960
	gcccggctca	ccgcaatctc	tgccacccg				
	<210> 54						
10	<211> 250						
	<212> DNA						
	<213> Human						
	<400> 54						
15	cattttcccca	ttggtcctga	tgttgaagat	ttagttaaag	aggctgtaag	tcaggttcga	60
	gcagaggcta	ctacaagaag	tagggaatca	agtocctcac	atgggctatt	aaaactaggt	120
	agtggtggag	tagtgaaaaa	gaaatctgag	caacttcata	acgtaactgc	ctttcagggg	180
20	aaagggcatt	cttttagaac	tgcatctggt	aaccacaccc	ttgatccaag	agctagggaa	240
	acttcagttg						
	<210> 55						
	<211> 2270						
25	<212> DNA						
	<213> Human						
	<400> 55						
30	gcgccccoga	gcagcgcccg	cgccctccgc	gccttctccg	ccgggacctc	gagcgaaaga	60
	ggccccgcgc	ccgcccagcc	ctcgctccc	tgcccaccgg	gcacaccgcg	ccgccacccc	120
	gaccccgctg	cgcacggcct	gtccgctgca	caccagcttg	ttggcgctct	cgtcgcgcgc	180
	ctcgcccccg	gctaactctg	cgcgccacaa	tgagctcccg	catcgccagg	gcgctgcct	240
	tagtcgtcac	ccttctccac	ttgaccaggc	tggcgctctc	cacctgcccc	gctgcctgcc	300
	actgccccct	ggaggcgccc	aagtgcgcgc	cgggagtcgg	gctggctcgg	gacggctgcg	360
35	gctgctgtaa	ggctgcgcgc	aagcagctca	acgaggactg	cagcaaaacg	cagccctgcg	420
	accacaccaa	ggggctggaa	tgcaacttcg	gcgcgaagtc	caccgctctg	aaggggatct	480
	gcagagctca	gtcagagggc	agaccctgtg	aataataactc	cagaatctac	caaaacgggg	540
	aaagtttcca	gcccactgt	aaacatcagt	gcacatgtat	tgatggcgcc	gtgggctgca	600
	ttcctctgtg	tccccaagaa	ctatctctcc	ccaacttggg	ctgtcccaac	cctcggtg	660
40	tcaaagttac	cgggcagtg	tgcgaggagt	gggtctgtga	cgaggatagt	atcaaggacc	720
	ccatggagga	ccaggacggc	ctccttggca	aggagctggg	attcgatgcc	tccgaggtg	780
	agttgacgag	aaacaatgaa	ttgattgcag	ttggaaaagg	cagctcactg	aagcggctcc	840
	ctgttttttg	aattggagcct	cgcctcctat	acaacccttt	acaaggccag	aaatgtattg	900
	ttcaaaacaac	ttcatgggtc	cagtgtctcaa	agacctgtgg	aactggtatc	tccacacgag	960
45	ttaccaatga	caaccctgag	tgccgccttg	tgaaagaaac	ccggatttgt	gaggtgcggc	1020
	cttgtggaca	gccagtgtac	agcagcctga	aaaagggcaa	gaaatgcagc	aagaccaaga	1080
	aatccccoga	accagtcagg	tttacttacg	ctggatgttt	gagtgtgaag	aaataccggc	1140
	ccaagtactg	cggttcctgc	gtggacggcc	gatgctgcac	gccccagctg	accaggactg	1200
	tgaagatgcg	gttccgctgc	gaagatgggg	agacattttc	caagaacgtc	atgatgatcc	1260
50	agtccctgca	atgcaactac	aactgcccgc	atgccaatga	agcagcgttt	cccttctaca	1320
	ggctgttcaa	tgacattcac	aaatttaggg	actaaatgct	acctgggttt	ccagggcaca	1380
	cctagacaaa	caagggagaa	gagtgtcaga	atcagaatca	tggagaaaaat	ggcggggggt	1440
	gggtgtgggtg	atgggactca	ttgtagaaag	gaagccttgc	tcattcttga	ggagcattaa	1500
	ggattttcga	aactgccaa	gggtgctggtg	cggatggaca	ctaattgcagc	cacgattgga	1560
55	gaatactttg	cttcatagta	ttggagcaca	tgttactgct	tcatttttga	gcttgtggag	1620
	ttgatgactt	tctgtttttt	gtttgtaaat	tatttgctaa	gcataattttc	tctaggcttt	1680
	tttccctttt	gggttctaca	gtcgtaaaag	agataataag	attagttgga	cagtttaaa	1740
	ctttttattcg	tccttttgaca	aaagttaaag	ggagggcatt	ccatcccttc	ctgaaggggg	1800
	acactccatg	agtgtctgtg	agagggcagct	atctgcactc	taaactgcaa	acagaaatca	1860
60	ggtgttttaa	actggaatgt	tttttttatc	aaaaatgtagc	ttttggggag	ggaggggaaa	1920
	tgtaatactg	gaataatttt	taaatgattt	taattttata	ttcagtgaag	agattttatt	1980
	tatggaatta	accattttaat	aaagaaatat	ttaccttaata	tctgagtgtg	tgccattcgg	2040
	tattttttaga	ggtgctccaa	agtcattag	aacaacctag	ctcacgtact	caattattca	2100
	aacaggactt	attgggatac	agcagtgaat	taagctatta	aaataagata	atgattgctt	2160
65	ttataccctt	agttagagaa	agtcctttgca	tataaagtaa	tgtttaaaaa	acatgtattg	2220
	aacacgacat	tgtatgaagc	acaataaaga	ttctgaagct	aaaaaaaaaa		

	<210> 56					
	<211> 1636					
	<212> DNA					
5	<213> Human					
	<400> 56					
10	cttgaatgaa gctgacacca agaaccgcgg gaagagcttg ggcccaaagc aggaaaggga 60					
	agcgctcgag ttggaaagga accgctgctg ctggccgaac tcaagcccgg gcgccccac 120					
	cagtttgatt ggaagtccag ctgtgaaacc tggagcgtcg ccttctcccc agatggctcc 180					
	tggtttgctt ggtctcaagg aactgcatc gtcaaactga tccccctggc gttggaggag 240					
	cagttcatcc ctaaagggtt tgaagccaaa agccgaagta gcaaaaatga gacgaaaggg 300					
	cggggcagcc caaaagagaa gacgctggac tgtggtcaga ttgtctgggg gctggccttc 360					
15	agcccgtggc cttccccacc cagcaggaag ctctgggcac gccaccacc ccaagtggcc 420					
	gatgtctctt gcctggttct tgctacggga ctcaacgatg ggcagatcaa gatctgggag 480					
	gtgcagacag ggctcctgct tttgaatctt tccggccacc aagatgtcgt gagagatctg 540					
	agcttcacac ccagtggcag tttgattttg gtctccgcgt cacgggataa gactcttcgc 600					
	atctgggacc tgaataaaca cggtaaacag attcaagtgt tatcgggcca cctgcagtgg 660					
20	gtttactgct gttccatctc cccagactgc agcatgctgt gctctgcagc tggagagaag 720					
	tcgggtctttc tatggagcat gaggtcctac acgttaattc ggaagctaga gggccatcaa 780					
	agcagtggtg tctcttgtag cttctcccc gactctgccc tgcttgtcac ggcttcttac 840					
	gataccaatg tgattatgtg ggacccctac accggcgaaa ggctgaggtc actccaccac 900					
	acccaggttg accccgccat ggatgacagt gacgtccaca ttagctcact gagatctgtg 960					
25	tgcttctctc cagaaggctt gtaccttgcc acggtggcag atgacagact cctcaggatc 1020					
	tggggccttg aactgaaaac tcccattgca tttgctccta tgaccaatgg gctttgctgc 1080					
	acattttttc cacatggtgg agtcattgcc acagggacaa gagatggcca cgtccagttc 1140					
	tggacagctc ctagggtcct gtccctcactg aagcacttat gccggaaaagc ccttcgaagt 1200					
	ttcctaacaa cttaccaagt cctagcactg ccaatcccca agaaaatgaa agagtctctc 1260					
30	acatacagga ctttttaagc aacaccaaat cttgtgcttc tttgtagcag ggtaaatcgt 1320					
	cctgtcaaag ggagttgctg gaataatggg ccaaaccatc ggtcttgcat tgaaatagca 1380					
	tttctttggg atttgtaata gaatgtagca aaaccagatt ccagtgtaca taaaagaatt 1440					
	tttttgtctt taaatagata caaatgtcta tcaactttaa tcaagttgta acttatattg 1500					
	aagacaattt gatacataat aaaaaattat gacaatgtcc tgggaaaaaa aaaatgtaga 1560					
35	aagatggtga aggtgaggat ggatgaggag cgtggtgacg ggggcctgca gcgggttggg 1620					
	gaccctgtgc tgcgtt					
	<210> 57					
	<211> 460					
40	<212> DNA					
	<213> Human					
	<400> 57					
45	ccatgtgtgt atgagagaga gagagattgg gagggagagg gagctcacta gcgcatatgt 60					
	gcctccaggg ggctgcagat gtgtctgagg gtgagcctgg tgaaagagaa gacaaaagaa 120					
	tggaatgagc taaagcagcc gcctggggtg ggaggccgag cccatttgta tgcagcaggg 180					
	ggcaggagcc cagcaaggga gcctccattc ccaggactct ggaggagct gagaccatcc 240					
	atgcccgag agccctccct cacactccat cctgtccagc cctaattgtg cagggtgggga 300					
50	aactgaggct gggaagtac atagcaagtg actggcagag ctgggactgg aaccaacca 360					
	gcctcctaga ccacggttct tcccatcaat ggaatgctag agactccagc cagggtgggta 420					
	ccgagctcga attcgtaatc atggtcatag ctgtttcctg					
	<210> 58					
55	<211> 1049					
	<212> DNA					
	<213> Human					
	<400> 58					
60	atctgatcaa gaatacctgc cctggctcact ctgcggatgt ttctgtccac ttgttcacat 60					
	tgaggaccaa gatatccttt tttacagagg cacttggtcg gtctaacaca gacacctcca 120					
	tgacgacatg ctggctcaca ttttgcagtt ctgcagaagt cccctcccca gcctggacta 180					
	cagcagcact ttcccgtggg ggtgcagtag ccgtttcgac agagcctgga gcactctgaa 240					
65	gtcagtgctt gtgcaggttg taccgtggct ctgcattcct caggcattaa aggtcttttg 300					
	ggatctacaa tttttagtag ttttccattg tgagtctggg tcatactttt actgcttgat 360					

5 aaaatgtaaa cttcacctag ttcattcttct ccaaatecca agatgtgacc ggaaaagtag 420
 cctctacagg acccactagt gccgacacag agtgggtttt cttgccactg ctttgtcaca 480
 ggactttgct ggagagttag gaaattccca ttacgatctc caaacacgta gcttccatac 540
 aatctttctg actggcagcc ccggtataca aatccacca ccaaaggacc attactgaat 600
 ggcttgaatt ctaaaagtga tggctcactt tcataatctt tcccctttat tatctgtaga 660
 attctggctg atgatctggt ttttccattg gagtctgaac acagtatcgt taaattgatg 720
 tttatatcag tgggatgtct atccacagca catctgcctg gatcgtggag cccatgagca 780
 aacacttcgg ggggctgggt ggtgctgttg aagtgtgggt tgctccttgg tatggaataa 840
 10 ggcacgttgc acatgtctgt gtccacatcc agccgtagca ctgagcctgt gaaatcactt 900
 aacccatcca tttcttccat atcatccagt gtaatcatcc catcaccaag aatgatgtac 960
 aaaaacccgt cagggccaaa gagcagttgc cctcccagat gctttctgtg gagttctgca 1020
 acttcaagaa agactctggc tgttctcaa

15 <210> 59
 <211> 747
 <212> DNA
 <213> Human

20 <400> 59

25 tttttcaaat cacatatggc ttctttgacc ccatcaaata actttattca cacaaacgtc 60
 ccttaattta caaagcctca gtcattcata cacattaggg gatccacagt gttcaaggaa 120
 cttaaata atgtatcata ccaacccaag taaaccaagt acaaaaaata ttcataataa 180
 gttgttcaca cgtaggtcct agattaccag cttctgtgca aaaaaaggaa atgaagaaaa 240
 atagatttat taactagtat tggaaactaa ctttgtgcct ggcttaaaac ctccctcacg 300
 ctgctctgtc ccacacaaat gtttaagaag tcaactgcaat gtactccccg gctctgatga 360
 aaagaagccc ctggcacaaa agattccagt gccctgaag aggtccctt cctcctgtgg 420
 gctctcctag aaaaaccagc ggacggcctc cctgctgata ccgtctataa ccttaggggg 480
 ccctcgggca ggcaacggca gtggactcat ctcggtgatg gctgtagatg ctaacactgg 540
 30 ccaattcaat gccacaccta ctggttacc tttgagggca tttctccaga cagaagcccc 600
 ttgaagccta ggtagggcag gatcagagat acaccgtgt ttgtctcgaa gggctccaca 660
 gccagtacg acatgcttgc agaagtagta tctctggact tctgcctcca gtcgaccggc 720
 cgcgaattta gtagtaatat cggccgc